20 Future Czech HealthTech and MedTech Leaders The healthcare technology and medical device sectors in the Czech Republic have reached a critical inflection point in 2026, transitioning from a regional innovation hub into a sophisticated global contender. This evolution is defined by a shift in capital allocation strategies, moving away from fragmented, early-stage experimentation toward a disciplined focus on profitability, clinical validation and scalable business models. As of early 2026, the European healthtech market, valued at approximately $96.68 billion, is navigating a period of strategic evolution influenced by a reorientation of investor priorities. Within this context, the Czech ecosystem, centred largely in the innovation corridors of Prague and Brno, has distinguished itself through a high concentration of deep tech expertise, robust academic spin-off frameworks, and a successful navigation of the rigorous European Medical Device Regulation (MDR). The resilience of the Czech sector is evidenced by its ability to secure significant funding rounds despite a 7.7% year-on-year decline in total investment for Czech founded startups in 2025, which totalled approximately €540 million. Notably, the healthtech vertical remained a cornerstone of this activity, with high-conviction "mega-deals" and strategic pre-seed rounds signaling a maturation of the ecosystem. This report identifies and analyses 20 pivotal leaders whose vision and technical execution are shaping the future of Czech healthtech and medtech, categorised by their impact on diagnostic intelligence, chronic disease management, advanced biotechnology and the burgeoning field of digital resilience. The Vanguard of Artificial Intelligence in Radiology and Diagnostics The integration of artificial intelligence into clinical workflows represents the most significant technological shift in Czech healthcare between 2024 and 2026. The focus has moved beyond the mere detection of pathologies to the creation of "unified AI platforms" that address the systemic issue of physician burnout and administrative overload. 1. Matěj Misař: Orchestrating the Unified AI Portfolio at Carebot Matěj Misař, as CEO and co-founder of Carebot, has transformed a startup focused on pneumonia detection into a leading European provider of comprehensive AI solutions for hospitals. Misař’s background in media and news hosting provided a unique skill set for navigating the complex public and regulatory dialogues surrounding AI adoption in medicine. In late 2025, Misař led the launch of the "Horizon by Carebot" portfolio, a strategic move designed to eliminate the technical barriers hospitals face when integrating multiple separate AI vendors. Under Misař’s leadership, Carebot secured MDR Class IIa certification, a critical milestone that validates the technology for use across the European Union. The company’s focus on "incidental detection", identifying early-stage lung cancer or other pathologies in routine imaging, has provided the clinical and economic justification necessary for widespread adoption. By 2026, Carebot has expanded its footprint beyond the Czech Republic into Southeast Asia (Vietnam) and the Middle East, demonstrating Misař’s ability to scale Czech innovation onto the global stage. 2. Daniel Kvak: The Scientific Architect of AI-Driven Clinical Practice Daniel Kvak, Carebot’s CTO, represents the next generation of Czech medical scientists who bridge the gap between complex machine learning and actual bedside utility. Kvak’s expertise in developing algorithms for chest X-ray analysis, mammography, and CT scans has earned him international recognition, including a place on the Forbes 30 Under 30 list and the " Personality.AI 2024" award. Kvak’s technical philosophy emphasises "explainable AI" and rigorous clinical validation. He has co-authored numerous award-winning scientific studies and serves as a reviewer for prestigious journals like European Radiology . By 2026, Kvak’s focus has shifted toward the development of the AI Bones module, which automates fracture detection, and the AI Head CT application for rapid identification of critical brain abnormalities. His work ensures that the Czech Republic remains a leader in the development of tools that reduce the diagnostic burden on radiologists while improving patient outcomes. Core Leader Primary Affiliation Key Achievement (2025-2026) Global Impact Area Matěj Misař Carebot Launch of Horizon Portfolio Hospital Workflow Optimization Daniel Kvak Carebot MDR Class IIa Certification for Multiple Modules Diagnostic Accuracy & Safety Marek Řehoř Carebot Scaling operations to 40+ European hospitals Operational Scalability Daniel Dufek Carebot Leading development of AI Head CT systems Emergency Radiology Cardiovascular Innovation and the Long-Term Monitoring Revolution The cardiovascular segment is undergoing a paradigm shift from acute care to continuous, AI augmented monitoring. This shift is necessitated by the high prevalence of heart arrhythmias that go undetected during standard clinical observation windows. 3. Vlastimil Hrabal: Scaling Cardiac Diagnostics into the DACH Region Vlastimil Hrabal, appointed as CEO of Kardi AI in April 2025, has been instrumental in the company’s transition from a promising Czech startup to a Series A-ready international medtech leader. Hrabal’s strategic focus on the DACH region (Germany, Austria, Switzerland) addresses the fundamental challenge of procurement and reimbursement in Western European healthcare systems. Kardi AI’s core product, an AI-powered chest strap that detects arrhythmias, addresses the "monitoring gap" where traditional 24-hour Holter monitors fail to capture rare or transient events. Hrabal has successfully positioned the company as a provider of "physician-ready outputs," reducing the review burden for cardiologists by delivering evaluated signal reports in an average of five minutes. This technical efficiency, combined with Hrabal’s leadership, has led to a doubling of sales and the launch of pilots across Bulgaria, Poland, Slovakia and Romania. 4. Prof. Tomáš Skála: Bridging Clinical Science and Wearable Technology As Chief Science Officer and co-founder of Kardi AI, Prof. Tomáš Skála provides the clinical gravitas necessary for a startup to be trusted by national healthcare providers. Skála, a practicing cardiologist, identified the inherent limitations of standard diagnostic tools and sought to create a "globally accessible, medically trusted" solution. Skála’s work focuses on the clinical validation of the AI layer, which evaluates ECG signals from a long-term chest strap.His research indicates a 30% detection rate for Kardi AI, which is roughly six times higher than traditional short window testing. By 2026, Skála is overseeing clinical trials at university hospitals in Olomouc and Ostrava, further strengthening the evidence base for continuous heart monitoring. His vision extends to making cardiac screening as routine and accessible as checking one's blood pressure, potentially preventing thousands of strokes and heart failure cases annually. Cardiovascular Leader AFFILIATION CORE INNOVATION FUNDING/STAGE Vlastimil Hrabal Kardi AI International scaling to DACH/CEE €1.1M Seed+ (2025) Prof. Tomáš Skála Kardi AI AI-driven long-term ECG analysis Series A Ready (2026) Stephen Burke Kardi AI Co-founder and Executive Director 3 Rounds Raised The New Frontier of Oncology and Genomic Medicine The Czech Republic’s biotechnology sector is increasingly defined by university spin-offs that target the fundamental molecular pathways of resistant diseases. These leaders are navigating the longest R&D cycles with high levels of strategic patience and technical precision. 5. Alexander Scheer: Leading the Global Charge Against Resistant Tumors Alexander Scheer, PhD, is the CEO and CSO of Casinvent Pharma, a Masaryk University spin-off that has become the leading Czech drug discovery company in 2026. Scheer brings over 25 years of international experience in the life science industry, having previously served as CSO for biotech companies in Belgium and France. At Casinvent, Scheer is advancing a unique "pan-isoform" approach to inhibiting the Casein Kinase 1 (CK1) family of enzymes. While many competitors focus solely on the alpha isoform, Scheer’s team has developed small-molecule inhibitors that simultaneously target the alpha, delta and epsilon isoforms. This approach is designed to bypass the adaptation pathways that cancers use to develop resistance to standard targeted therapies. By mid 2026, Scheer is preparing the company for its IND (Investigational New Drug) filing and entry into clinical Phase Ia/b trials, supported by a Series A funding target of €10-12 million. 6. Tomasz Radaszkiewicz: The Biological Engine Behind Next-Generation Inhibitors Tomasz Radaszkiewicz serves as the Head of Biology at Casinvent Pharma and is a central figure in the identification of novel therapeutic strategies for Wnt-driven malignancies. Radaszkiewicz’s work involves the rigorous screening of over 500 candidates to select lead compounds with exceptional in vivo efficacy in treating acute myeloid leukemia (AML), melanoma, and pancreatic cancer. Radaszkiewicz’s role is critical for providing the biological evidence that supports the company’s intellectual property claims and attracts institutional investors like KHAN-I and JIC Ventures. His leadership in biological research has led to significant publications in journals like Cell Reports Medicine , positioning Casinvent as a scientifically superior alternative to current targeted degraders. 7. Petr Cigler: Pioneering Advanced Lipid Nanoparticle Technology As Chief Scientific Officer of Adalid Sciences, Petr Cigler is addressing the global "delivery bottleneck" for genomic medicines. Adalid, founded in 2024, focuses on the development of lipid nanoparticle (LNP) systems that transport nucleic acids, such as mRNA and gene-editing tools, into human cells. Cigler’s strategic innovation lies in the company’s "integrated IP portfolio," which focuses on new ionizable compounds and lipid-polymer conjugates. This technology eliminates the need for pharmaceutical companies to source delivery components from multiple vendors, streamlining the development of RNA therapeutics. Under Cigler’s scientific guidance, Adalid has built a diverse library of several patent families focused on flexible and constrained lipids, providing precise control over particle design for specific payloads. 8. Andrea Brazdova: Validating the Future of RNA Delivery Andrea Brazdova, PhD, is the Head of Biology at Adalid Sciences, where she leads the biological validation of next-generation LNPs. Brazdova is a senior immunologist with postdoctoral training in cellular therapy and immuno-regulation. Her work at Adalid involves linking formulation design with in vitro functionality and in vivo validation, ensuring that nucleic acid medicines reach their clinical impact. Brazdova’s expertise in immune response characterization is particularly relevant as the industry moves toward localized and systemic delivery routes for complex gene editing. Her leadership in screening LNP candidates against human primary cells ensures that Adalid’s solutions are optimised for safety and efficacy before they reach clinical trials. Biotech Leader Affiliation Technology Focus Role in Ecosystem Alexander Scheer Casinvent Pharma CK1 $\alpha/\delta/\epsilon$ Inhibitors Global Strategic Leadership Tomasz Radaszkiewicz Casinvent Pharma Wnt-driven Malignancy Research Clinical Strategy & Biology Petr Cigler Adalid Sciences LNP Structural Differentiation IP Development & Chemistry Andrea Brazdova Adalid Sciences Biological Validation of RNA Delivery Preclinical Translation Digital Resilience and the Evolution of Mental Health Technology Mental health has emerged as one of the most attractive investment targets in 2025-2026, with total M&A value in the CNS (Central Nervous System) segment reaching over $30 billion. Czech leaders are pioneering a new category of "digital resilience" that uses AI to mitigate the negative psychological impacts of the digital environment. 9. Jan Romportl: The Visionary Behind "Cognitive Antivirus" Dr. Jan Romportl, co-founder and CEO of Elin.ai , is a leading expert in cybernetics and AI ethics who has pivoted his expertise toward the growing mental health crisis among Generation Z. Elin.ai , founded in 2023, develops an AI-powered assistant designed to support users in challenging digital environments. Romportl’s "cognitive antivirus" concept works as a protective layer for the brain, helping users recognise digital overload and algorithmic pressure before they lead to "brainrot" or anxiety. Under Romportl’s leadership, Elin.ai raised a €1 million pre-seed round to further develop its empathetic dialogue LLMs (Large Language Models), which are trained in close collaboration with clinical experts to detect distress signals and provide proactive interventions. His work represents a shift from reactive therapy to preventive digital well-being. 10. Soňa Sikorová: Scaling Digital Therapeutics for Chronic Psychiatry Soňa Sikorová is the CEO and co-founder of Mindpax, a digital therapeutics company that has become a global leader in the management of bipolar disorder. Mindpax utilises a combination of long-term symptom monitoring (via actigraphic sensors) and targeted digital therapy to improve the clinical condition of patients. Sikorová has been instrumental in securing large-scale commercialization partnerships, most notably with EVERSANA in the United States, to launch Mindpax’s solution as a regulated digital therapeutic. Her leadership focuses on evidence generation; Mindpax has conducted years of clinical studies to develop the world's largest dataset of its kind for bipolar patients. By 2026, Sikorová is steering the company toward full integration with U.S. and European healthcare systems, utilizing AI-powered data insights to optimize treatment outcomes in real-time. 20 Future Czech HealthTech and MedTech Leaders 11. Jiří Horáček: The Bridge Between Neuroscience and AI Startups Professor Jiří Horáček is a psychiatrist, neurobiologist, and co-founder of both Elin.ai and Mindpax. His influence in the Czech medical community is profound; he has published over 200 scientific articles and is recognized as one of the "TOP 50 Doctors" in the Czech Republic. Horáček’s leadership provides the scientific legitimacy required for AI startups to operate in the highly regulated field of clinical psychiatry. He specialises in brain imaging and the use of biomarkers to understand affective disorders. Within Elin.ai , he oversees the training of AI models to ensure they remain non-toxic and empathetic, while at Mindpax, his research into circadian rhythms and suprachiasmatic nuclei (SCN) functioning forms the basis of the company’s monitoring algorithms. Mental Health Leader Project Key Concept Impact Goal Jan Romportl Elin.ai Cognitive Antivirus Digital Resilience for Gen Z Soňa Sikorová Mindpax Digital Therapeutics (DTx) Long-term Bipolar Management Jiří Horáček Elin.ai/Mindpax Empathetic AI Dialogue Scientifically Validated Well-being Lukas Krcil Hedepy Accessible Online Therapy Stigma-free Mental Healthcare Precision Medicine, Longevity and Data Aggregation The "longevity" market focused on extending the healthy human lifespan is moving from wellness hype toward data-driven precision medicine. Czech leaders are building the platforms that unify disparate health data into actionable insights. 12. Petr Štěpánek: The Entrepreneurial Force Behind Macromo Petr Štěpánek, CTO and co-founder of Macromo, is a serial entrepreneur who founded his first project at the age of 16 and has since become a central figure in the Prague startup community. Macromo serves as a health data aggregator, providing users with a holistic view of their health by combining DNA results, blood biomarkers and lifestyle data from wearables. Štěpánek’s vision is to use AI to provide everyone with a "personal health coach" that transforms raw data into clarity. His technical leadership led to the creation of the Macromo Engine, a cloud-based bioinformatics system that contextualises biomarkers over time to identify unique health risks and opportunities. Štěpánek’s proactive approach to fundraising, including independent trips to Silicon Valley to build investor networks, underscores his ambition to take Czech precision medicine technology global. 13. Michal Pohludka: Driving the Clinical and Commercial Bridge Michal Pohludka, PhD, MBA, is a biochemist with a background in molecular pathology and the CEO of GeneSpector and co-founder of Macromo. Pohludka represents the "business scientist" archetype, capable of navigating the extremely regulated pharmaceutical and medical fields. Under Pohludka’s leadership, GeneSpector succeeded in the COVID-19 diagnostic market (generating over $25 million in sales) and subsequently pivoted to global diagnostics for kidney disease and other chronic conditions. His strategy focuses on technology transfer, moving projects from the laboratory to the market through licensing or spin-offs. At Macromo, Pohludka leverages this commercial expertise to build partnerships with certified laboratories and ensure that personalised healthcare is both accessible and actionable. Medtech Infrastructure, Hardware and Biomimetic Innovation Hardware and physical medical devices remain critical for surgical advancement and patient safety. Czech leaders in this segment are using nanotechnology and biomimetic principles to revolutionise traditional procedures. 14. Markéta Hujerová: Revolutionizing Surgery with Nanofiber Patches Markéta Hujerová (née Klíčová) is the founder of Nanoflexion, a spin-off from the Technical University of Liberec.Hujerová’s work centres on the development of a nanofiber surgical patch designed to prevent serious complications after intestinal surgery, such as anastomotic leakage and adhesions. Hujerová’s innovation addresses a critical clinical need: sepsis following colon surgery currently kills up to 22% of affected patients. The nano-patch acts as a biological barrier and carries drugs to suppress inflammation and promote healing. In late 2025, Hujerová signed a pivotal incubation agreement with i&i Prague and Charles University to commercialise the technology and move toward human clinical trials. Her journey from academic research to presenting her project at the World Expo in Osaka illustrates the potential for Czech female scientists to lead global medtech ventures. 15. Miroslav Svoboda: The Snail-Eye Inspiration for Patient Comfort Miroslav Svoboda, MD, is the CEO and project initiator of Riocath Global, a company that has developed a revolutionary technology for tubular medical devices. The RIOCATH® mechanism, inspired by the unfolding of a snail’s eyestalk, allows for a double-skinned catheter that extends from the inside out. Svoboda’s invention significantly reduces the risk of infection and tissue damage during catheterisation, a major issue in hospitals worldwide. By virtually eliminating the friction between the catheter casing and the urethra wall, the technology makes for safer and more comfortable patient care, potentially saving healthcare systems millions in antibiotic costs for urinary tract infections. Svoboda’s ability to raise over two million euros from private investors and secure global patents through the European Patent Office marks him as a leader in Czech bio-mechanical innovation. 16. Jiří Kuchyňa: Advancing Scalable AI in Ophthalmology Jiří Kuchyňa is the CEO of Aireen, a startup that has developed a fundus-camera-agnostic AI system for chronic disease screening through retinal analysis. Under Kuchyňa’s leadership, Aireen achieved a strategic partnership with Optomed to integrate its AI algorithm into handheld fundus cameras, making diabetic retinopathy screening more accessible than ever. Kuchyňa’s focus on scalability addresses a major public health challenge: the need for sensitive and accurate screening of chronic diseases without requiring a visit to a specialist. By 2026, Kuchyňa is positioning Aireen as a critical component of primary care, enabling early detection of diseases that would otherwise lead to permanent blindness. Medtech Infrastructure Leader AFFILIATION CORE TECHNOLOGY IMPACT Markéta Hujerová Nanoflexion Nanofiber Surgical Patch Post-Surgical Sepsis Prevention Miroslav Svoboda Riocath Global Double-skinned Catheter Infection Risk Reduction Jiří Kuchyňa Aireen Retinal AI Screening Accessible Ophthalmology Pavel Rozsíval Viderai High-speed Retinal Analysis Mass-Screening Populations Emerging Disruptors and the Institutional Backbone The long-term success of the Czech healthtech ecosystem is contingent upon leaders who build the infrastructure for innovation and venture capital, as well as those who pivot established tech success into the medical field. 17. Jan Studnička: Leading the Mass-Screening Effort at Viderai Jan Studnička, PhD, is a vitreo-retinal specialist and a core leader at Viderai, an innovative startup aimed at making retinal screening affordable for the general population. Studnička’s clinical expertise in age-related macular degeneration and diabetic retinopathy ensures that Viderai’s AI algorithms deliver specialist-level sensitivity (99%) in routine scans. Viderai’s mission, supported by Studnička’s clinical leadership, is to lower public healthcare expenses by detecting disorders early through mass-screening applications. By automating the routine work of analysing eye scans, Studnička and his team are increasing the examination capacity of clinics, allowing ophthalmologists to focus on complex surgical cases while the AI handles the bulk of the population screening. 18. Otomar Slama: The Catalyst for Science-to-Business Transfer Otomar Slama is a co-founder of GeneSpector and a key figure in the Czech "spin-off" ecosystem. His work focuses on the commercialisation of academic research, bridging the gap between discovery and market-ready clinical diagnostics. Slama’s leadership within GeneSpector has helped create a portfolio of solutions for nucleic acid extraction and PCR-based diagnostics that compete with global giants like Natera and GeneDx. Slama’s influence extends beyond a single company; he is a model for how technology transfer offices and university funds can successfully navigate the complexities of patents, licensing and venture building. His work ensures that the Czech scientific output in biomedicine is not just academic, but industrially viable and beneficial to the national economy. 19. Karel Kubias: Navigating the Venture Capital Life Science Wave Karel Kubias, MBA, is a Founding Partner at the i&i Biotech Fund (i&i Bio), one of the few VC funds in Central Europe focused exclusively on life science ventures. With over 20 years of leadership experience in pharma and diagnostics (including roles at Merck), Kubias is a critical gatekeeper and accelerator for Czech healthtech leaders. Under Kubias’s guidance, the i&i Biotech Fund, established in cooperation with the European Investment Fund (EIF), is investing over €45 million into academic spin-offs in drug discovery, medical devices and digital health. Kubias’s role is to identify founders with a "clear edge" and provide the capital and strategic guidance required to take Czech innovations global. His leadership at the fund level is what enables leaders like Alexander Scheer and Markéta Hujerová to move from proof-of-concept to clinical reality. 20. Barbora Šumová: Identifying the Next Wave of Medtech Success Barbora Šumová, PhD, is a Partner at i&i Bio and a specialist in innovative biotech and medtech ventures. With a PhD in Immunology, Šumová brings deep technical understanding to the investment process, allowing the fund to vet complex biological and technical claims that traditional VCs might miss. Šumová’s leadership in portfolio management and board leadership is vital for the growth of companies like Casinvent Pharma. She represents a new generation of Czech female investment leaders who are shaping the national landscape by focusing on high-tech innovations that fundamentally improve patient care. Her work ensures that the Czech Republic remains competitive in the European healthtech scene through 2026 and beyond. Strategic Market Dynamics: The 2026 Narrative The Czech healthtech landscape is being reshaped by several overarching trends that dictate the strategies of these 20 leaders. The first is the acceleration of digital transformation and AI, with 48% of life science leaders identifying this as the most substantial trend for 2026. The proliferation of generative AI is no longer a peripheral experiment but a core driver of clinical operations and research efficiency. Furthermore, the rise of MDR as a competitive moat cannot be understated. While the regulation is often viewed as a burden, for Czech leaders like Carebot and Kardi AI, achieving MDR Class IIa certification has become a mark of quality that facilitates market entry into the conservative DACH region and beyond. This regulatory hurdle has effectively filtered out less disciplined competitors, leaving a concentrated group of high-impact players. The third major trend is the rise of defence-linked biotech and dual-use innovation. The selection of Czech-linked technologies for the NATO DIANA 2026 cohort underscores a new geopolitical reality: biotechnology is now a core pillar of national and regional security. Funding for "human resilience" and "trauma diagnostics" through NATO and EU instruments provides a new, non-dilutive capital source for Czech medtech leaders that was largely absent five years ago. Investment Landscape and Regional Competitiveness The distribution of capital in 2025 and 2026 favours those who can demonstrate a "right to grow" through effective capital allocation and the integration of high-growth acquisitions. Although total venture funding in the CEE region remains heavily influenced by a handful of large transactions, the steady flow of seed and seed+ deals in the Czech Republic highlights an ecosystem that is deep and resilient. Fund/Investor FOCUS AREA NOTABLE INVESTMENT i&i Biotech Fund Academic Spin-offs, Biotech, Medtech Casinvent Pharma JIC Ventures Deep Tech, SaaS, CEE Early Stage Casinvent Pharma Presto Ventures Early-stage B2B and AI Elin.ai Rockaway Ventures AI-driven Disruptors ValkaAI (Interactive Video) DEPO Ventures Angel-led early-stage medtech Kardi AI The emergence of Brno as a secondary but equally powerful hub for life sciences, particularly in oncology and university-driven medtech, complements Prague’s dominance in software-centric healthtech. This regional synergy creates a diverse national portfolio that can weather shifts in specific technological sub-sectors. Conclusion: The Horizon of 2027 and Beyond By 2027, the Czech healthtech and medtech sectors are poised to move from "market expansion" into "market leadership" in several niches, specifically AI-enabled radiology and cardiac monitoring. The 20 leaders profiled in this analysis are not just building companies; they are constructing the "AI factories" and "biotech hubs" that will define European healthcare for the next decade. The core challenge for these leaders moving forward will be navigating the fragmented global landscape. While optimism remains high, with 75% of medtech executives confident in their financial outlook for 2026, this confidence is tempered by geopolitical tensions and pricing pressures. The successful Czech leader of 2027 will be one who adopts an "agile operating model," builds "robust external partnerships," and continues to unite technical discovery with patient care. As the industry matures beyond the initial AI hype toward measurable productivity, the Czech Republic’s commitment to scientific rigor and regulatory compliance positions it as one of the most promising tech hubs in Europe. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Portuguese HealthTech and MedTech Leaders Evolutionary Dynamics of the Portuguese Healthtech Ecosystem: A Comprehensive Analysis of 20 Emerging Leaders and Technological Frontiers The Portuguese healthtech and medtech landscape has reached a state of systemic maturity, transitioning from a localized cluster of academic spin-offs to a formidable international player in precision medicine, digital surgery, and biotechnology. By the mid-2020s, the national startup ecosystem recorded a 16% increase in active ventures, totalling over 4,700 companies, of which nearly 70% were founded within the preceding five-year window. This acceleration is not merely numerical but represents a qualitative shift toward high-complexity "Deep Tech" and "Fusion Research," where the barriers between laboratory investigation and clinical implementation are systematically dismantled. The influx of venture capital, reaching €886 million in 2024, a 55% increase over previous years, has provided the necessary liquidity for Portuguese leaders to compete on a global stage, particularly in AI-driven care and sustainable biotechnology. The Strategic Macro-Environment of Portuguese Life Sciences The transformation of Portugal into a European health innovation hub is underpinned by several structural factors. First, the decentralisation of innovation beyond Lisbon and Porto has created a "vibrant innovation corridor" encompassing Coimbra and Aveiro supported by academic anchors and regional funding initiatives. Second, the "Startup Visa" and national funding schemes have established a fertile ground for international talent and capital. Third, the role of institutional "anchors" such as the Champalimaud Foundation and the Institute for Research and Innovation in Health (i3S) has provided the infrastructure for high-risk, high-reward medical breakthroughs. In this environment, leadership is defined by the ability to navigate the "valley of death" between research and commercialisation. The current vanguard of Portuguese healthtech leaders is characterized by a high degree of technical expertise, often holding advanced PhDs or clinical backgrounds, and a strategic focus on export-driven growth. The following sections analyse 20 of these leaders, categorising their influence by technological domain and institutional impact. The Vanguard of AI-Driven Care and Digital Infrastructure The most significant capital injections in the Portuguese healthtech sector have concentrated on Artificial Intelligence (AI) solutions that address clinical labor shortages and diagnostic inefficiencies. Virgílio Bento: Scaling the AI-First Care Paradigm Virgílio Bento, the founder and CEO of Sword Health, represents the apex of Portuguese healthtech entrepreneurship. As of early 2026, Sword Health reached a Series Junior post-money valuation of $4.36 billion, positioning it as one of the most valuable private healthtech companies globally. Bento’s strategic vision centers on shifting healthcare from a "human-first" to an "AI-first" model, a transition necessitated by the global shortage of clinical professionals. Under Bento's leadership, Sword Health has expanded its scope from musculoskeletal (MSK) therapy to comprehensive mental health support with the launch of "Mind" in 2025. This platform utilises a proprietary wearable device, the M-band, to detect early biomarkers of depression and anxiety, enabling proactive outreach by clinicians. Bento’s execution has successfully attracted major international investors, including General Catalyst and Khosla Ventures, and the company has reportedly saved clients nearly a billion dollars in unnecessary healthcare costs by preventing avoidable surgeries. His stated goal of pursuing an initial public offering (IPO) by 2028 reflects a long-term commitment to rebuilding care delivery through foundational AI research. Tiago Cunha Costa: Revolutionising Diagnostic Interpretation Tiago Cunha Costa, founder and CEO of BloodFlow, is addressing a systemic bottleneck in hospital workflows: the interpretation of laboratory results. Founded in 2024 and based in Lisbon, BloodFlow utilises an AI-powered platform for automated blood test interpretation. Costa, a former high-performance swimmer, identified the inefficiency of manual data analysis during his athletic career, where raw data often lacked the clinical context necessary for immediate action. BloodFlow’s "FlowCore" technology is distinguished by its native integration within Electronic Health Record (EHR) systems using HL7 FHIR standards. This approach ensures data sovereignty, as clinical data is processed entirely on-premise without transferring patient information outside the provider's infrastructure, a critical factor for regulatory compliance and physician trust. In 2025, Costa secured a €1.2 million seed round from 3xP Global, enabling the company to scale its "invisible automation" across European markets. José Bastos: Defining the Digital Front Door José Bastos, co-founder and CEO of knok healthcare, has been a central figure in the maturation of Portuguese telemedicine. knok operates a "Digital Front Door" strategy, connecting patients, providers, and healthcare professionals through a seamless digital interface. Supported by Armilar Venture Partners, Bastos has steered the company toward late-stage VC rounds, focusing on the integration of digital health solutions into the current frameworks of major healthcare providers. His leadership at knok reflects a broader shift toward patient-centric platforms that prioritise accessibility and motivation throughout the recovery journey. Henrique Martins: Architect of Digital Health Strategy Professor Henrique Martins, associated with ISCTE-IUL and UBI, is a pivotal leader in the policy and management of digital health in Portugal. As a digital health consultant and a key voice in the Portuguese eHealth Strategy, Martins bridges the gap between technological possibility and regulatory reality. His work emphasizes the "democratisation of access" and the need for scalable implementation of AI and digital tools in everyday clinical practice. Martins’ influence extends to European policy, where he contributes to discussions on health data hubs and the secondary use of healthcare data. Leader Company/Institution Core Technology Recent Milestone Virgílio Bento Sword Health AI Physical/Mental Therapy $4.36B Valuation (Jan 2026) Tiago Cunha Costa BloodFlow AI Diagnostic Analysis €1.2M Seed Round (July 2025) José Bastos knok healthcare Telemedicine Platform Late VC Round backing (May 2025) Henrique Martins ISCTE-IUL / UBI Digital Health Strategy Lead voice in Portuguese eHealth Strategy Pioneers of the Surgical Metaverse and Advanced Oncology The Champalimaud Foundation has emerged as a global leader in "Fusion Research," particularly in the development of augmented reality (AR) and digital twin technologies for oncology. Pedro Gouveia: Architect of the Surgical Metaverse Dr. Pedro Gouveia, a breast surgeon and researcher at the Champalimaud Clinical Centre, is the primary visionary behind the "MetaBreast" project. Gouveia’s work centres on the "Surgical Metaverse," where AR goggles connected to a health data cloud allow surgeons to superimpose 3D digital twins of tumors directly onto a patient's body in the operating room.This non-invasive, image-guided precision surgery aims to ensure clear surgical margins and reduce the need for repeat operations. Supported by approximately €1.4 million in funding from the Portuguese Resilience and Recovery Plan (PRR), Gouveia has established a Digital Surgery Lab that combines AI, computer vision, and immersive visualization. His leadership is characterised by a focus on "technological literacy" and the removal of cognitive burdens for surgeons, facilitating better-informed decision-making at scale. Markus Büchler: Transforming Pancreatic Cancer Care Professor Markus W. Büchler, an internationally renowned pancreatic surgeon with a record of over 3,000 surgeries, was appointed Director of the Botton-Champalimaud Pancreatic Cancer Centre in April 2023. Büchler’s arrival in Lisbon signifies Portugal’s ability to attract top-tier global talent to lead multidisciplinary teams of surgeons, scientists, and computational biologists. The Centre, funded by a €50 million partnership with the Mauricio and Charlotte Botton couple, is the first in the world to simultaneously integrate research and treatment for pancreatic cancer. Under Büchler’s direction, the Centre utilises a BSL-2-compliant cGMP Gene Therapy Facility to produce CAR-T cells for clinical trials, embodying a translational methodology that brings innovations swiftly into clinical practice. Tiago Marques and João Santinha: Leading Deep Learning in Radiology Within the Marques-Santinha Lab at the Champalimaud Foundation, Tiago Marques and João Santinha lead the development of AI algorithms designed to enhance the accuracy of screening and diagnosis. Their research leverages deep learning to segment fat and fibroglandular tissue in MRIs, which is essential for creating the precise 3D digital twins used in Gouveia's surgical metaverse. By focusing on the "generalisability and robustness" of AI models, Marques and Santinha are accelerating the clinical adoption of these tools across diverse healthcare settings. Albino Oliveira-Maia: Integrating AI into Neuropsychiatry As the Director of the Neuropsychiatry Unit at the Champalimaud Foundation, Albino Oliveira-Maia is at the forefront of applying AI to mental health diagnostics. His work involves exploring how digital neuro-therapeutics and AI virtual assistants can revolutionise medical practice and research in neuropsychiatry. Oliveira-Maia’s leadership is critical in bridging the foundation's strengths in neuroscience with the emerging capabilities of generative AI and medical imaging. Leaders in Biotechnology and Sustainable Nutrition The Portuguese biotech sector is experiencing a renaissance in "Blue Biotechnology" and precision fermentation, addressing global challenges in nutrition and resource sustainability. Ali Osman: Driving Precision Fermentation for Human Health Ali Osman, founder and CEO of PFX Biotech, is a central figure in the development of human milk proteins via precision fermentation. Based in Porto and incubated at UPTEC, PFX Biotech uses engineering biology to produce functional ingredients such as lactoferrin, which is associated with immune system support and iron regulation. In mid-2025, Osman secured a total of €5 million in funding, including a €2.5 million seed round led by Buenavista Equity Partners and a matching €2.5 million grant from the EIC Accelerator. Osman’s team combines deep operational know-how with scientific depth, aiming to make precision fermentation commercially viable at scale. PFX Biotech’s proteins provide a safer, allergen-free alternative for infant formulas and advanced nutrition for the elderly and athletes. 9. Vítor Verdelho: Pioneering Cellular Aquaculture Vítor Verdelho, CEO of Cell4Food, is leading the first Portuguese company dedicated to cellular aquaculture. A spin-off from the University of Porto, Cell4Food is developing technologies to produce cell-based seafood, beginning with octopus cells ( Octopus vulgaris ). Verdelho’s strategy centers on a B2B model, creating and licensing technological platforms for the agri-food industry to support more sustainable and resilient food systems. In early 2026, Cell4Food secured €1.5 million to advance its cell-based seafood innovation, utilizing AI-powered bioprocess modeling to reduce trial-and-error experimentation by 80%. Verdelho’s vision positions Portugal as a relevant player in the European blue transition, dissociating food production from the direct exploitation of marine resources. Bruno Sarmento: Advancing Nanomedicine and Drug Delivery Professor Bruno Sarmento, a researcher at i3S and co-founder of the spin-off Inovapotek, is a global leader in controlled drug delivery systems. In 2026, Sarmento will assume the presidency of the Controlled Release Society, the largest international scientific society in the field. His research focuses on the development of functionalised nanomedicines for diabetes, cancer, and infectious diseases, as well as three-dimensional tissue engineering models for the in vitro validation of these medicines. Sarmento’s leadership at i3S and his involvement in global pharmaceutical nanotechnologies highlight Porto's role as a major hub for translational drug delivery research. Innovators in Immunotherapy and the Fight Against AMR The challenge of Antimicrobial Resistance (AMR) has spurred the development of novel immunotherapies by leaders who are redefining how we treat infectious diseases. Bruno Santos and Pedro Madureira: Neutralising Bacterial Virulence Bruno Santos (CEO) and Pedro Madureira (CSO) are the co-founders of Immunethep, a biotechnology company that originated as a spin-off from the University of Porto. Immunethep’s innovation is based on Madureira’s discovery of a virulence mechanism shared by life-threatening bacteria, such as E. coli and K. pneumoniae . The bacteria release a protein variant called bGAPDH, which shifts the host’s immune response toward an anti-inflammatory state, making the body more susceptible to infection. Under their leadership, Immunethep has developed the "Paragon Novel Vaccine" (PNV), the first in the world to simultaneously prevent infections from five critical bacteria. In 2025, the company received $2 million from CARB-X and additional funding from PACE to advance its monoclonal antibody program. Santos’s background in biological engineering and MBA training complements Madureira’s scientific discoveries, moving Immunethep toward human clinical trials and international partnerships with top pharma companies. Leader Company Focus Area Impact Metric Ali Osman PFX Biotech Precision Fermentation €5M Seed/Grant (2025) Vítor Verdelho Cell4Food Cellular Aquaculture €1.5M Portugal 2030 (2026) Bruno Santos Immunethep AMR Immunotherapy $2M CARB-X Funding (2025) Bruno Sarmento i3S / Inovapotek Nanomedicine President-Elect Controlled Release Society Leaders in Medtech and Bioengineered Materials Materials science and bioengineering in Portugal are producing leaders who are developing autonomous, battery-free medical devices and advanced diagnostic tools. 12 Andreia T. Pereira: Pioneering Batteryless Medical Devices Andreia T. Pereira, a junior researcher at i3S, is at the vanguard of "BioTribo," a research line focusing on energy-harvesting systems for biomedical use. Her work involves using the human body as an inexhaustible energy source to power smart medical devices, such as pacemakers, through triboelectric nanogenerators. Pereira’s research also includes developing graphene-based composites for blood-contacting devices that prevent thrombosis and bacterial adhesion. Her contributions have been recognized with the Maria de Sousa Prize and the L'Oréal Portugal Honor Medal for Women in Science. Alexandre Barros: Advancing Biodegradable Medtech Alexandre Barros, the CEO and Business Development Manager at Hydrumedical (Hydrustent SA), has led the commercialisation of biodegradable urological stents. Hydrumedical's patented technology allows for the creation of the first 100% biodegradable ureteral stent, which avoids the need for a second surgery and reduces treatment costs by 60%. Under Barros’s leadership, the company has expanded into stoma care and infection control lines, achieving international certifications (ISO 13485) and establishing a certified production site in Guimarães. Ricardo Moura: Scaling Anthropometric Ecosystems Ricardo Moura, co-founder and CEO of Wisify Tech Solutions, has built a measurement ecosystem trusted by sports nutritionists and performance teams globally. Wisify’s products, Lipowise and Gripwise, are digital devices for evaluating body composition and muscle strength, connecting hardware and software to monitor frailty and sarcopenia. Moura’s leadership has focused on creating a complete clinical workflow that makes precision measurement accessible and actionable for professionals in five markets. Diana S. Nascimento: Innovating Cardiovascular Regeneration Diana S. Nascimento, an investigator at i3S and professor at ICBAS, is a leader in bioengineered therapies for cardiovascular disorders. Her research focuses on heart repair using piezoelectric materials to drive cardiac regeneration and inhibit fibrosis. Nascimento’s work bridges fundamental and applied research, addressing the formation of fibrosis and the aging of the extracellular matrix after injury, contributing significantly to the field of regenerative medicine in Portugal. Strategists in Digital Health and Professional Efficiency The broader digital health ecosystem in Portugal is shaped by leaders focused on clinical efficiency, professional networking, and long-term ecosystem development. Joana Pinto: Gamifying Physiotherapy Joana Pinto, co-founder and CEO of Clynx, is redefining physiotherapy delivery through gamification. A participant in the 2018 EIT Health InnoStars Awards, Clynx improves the patient experience by supporting flexible, motivating care. Pinto has been recognised as one of Europe's most influential women in the startup space, highlighting the potential of gamified digital health tools to ease pressure on healthcare systems. José Paulo Carvalho: Scaling Remote Patient Monitoring José Paulo Carvalho, founder and board member of Hopecare, is a pioneer in remote patient monitoring in Portugal. His work focuses on integrating digital health into current clinical frameworks, helping patients manage chronic conditions from home. Carvalho’s role as an executive board member at TICE.PT highlights his influence in the Portuguese information and communication technology cluster for health. Cláudio Costa: Leading Clinical Research and Intelligence Cláudio Costa, CEO and founder of ActOne Intelligence & Research, is a key figure in the application of intelligence and data analytics to clinical research. ActOne focuses on providing deep insights that drive decisions in the life sciences sector, reflecting the growing importance of analytics in the Portuguese healthtech landscape. David Magboulé: Facilitating Technology Transfer David Siqueira Magboulé, CEO at LabtoMarket, is a leader in bridging the gap between academic research and commercial applications. LabtoMarket works with researchers and institutions to identify market-ready technologies and facilitate their transition into the healthcare ecosystem. His leadership is essential for the continuous flow of innovation from Portugal's strong academic base to the global market. Filipa Fixe: Steering Corporate Health Innovation Filipa Fixe, as an executive leader at Glintt Global, oversees one of the largest technology and consulting groups in the Iberian Peninsula focused on healthcare. Her work involves managing digital health solutions for hospitals and pharmacies, ensuring that large-scale clinical institutions can adopt and integrate the innovations coming from the startup ecosystem. Fixe’s role is critical for the "robustness and transparency" of healthcare processes at the corporate level. Technical Foundations: A Comparative Analysis of Medtech Innovations The leadership demonstrated by these 20 individuals is deeply rooted in the technical superiority and unique mechanisms of their respective technologies. The following table provides a comparative overview of the core technological drivers for selected leaders. Leader Primary Platform Technical Mechanism Strategic Implication Pedro Gouveia MetaBreast / AR 3D-Digital Twin Superposition Precision surgery; zero repeat procedures Tiago C. Costa FlowCore / AI HL7 FHIR Native EHR Processing Data sovereignty; zero external data transfer Pedro Madureira Immunethep / PNV bGAPDH Neutralization Anti-bacterial therapy without AMR risk Andreia T. Pereira BioTribo / Nanogen Triboelectric Energy Harvesting Battery-free, autonomous implants Vítor Verdelho Cell4Food Cellular Blue Biotechnology Sustainable seafood; resource dissociation Virgílio Bento Sword AI Multi-modal Deep Learning Unlocking $MSK$ and mental health access Institutional Synergy and the "Fusion Research" Model The emergence of these leaders is not an isolated phenomenon but the result of a deliberate "Fusion Research" model adopted by Portuguese institutions. The Champalimaud Foundation and i3S exemplify this by housing surgical services, research labs, and clinical trials under one roof. The Champalimaud Centre for the Unknown: A Catalyst for Metaverse Surgery The architecture and mission of the Champalimaud Centre for the Unknown (CCU) are designed to "bridge the gap between laboratory and clinic". This environment allows leaders like Gouveia and Büchler to test digital surgery solutions in "Immersive Surgical Arenas" that mimic real operating rooms. The creation of a health data cloud infrastructure by CCU scientists ensures that medical data can be transferred and stored securely, virtually via the internet, which is a prerequisite for the commercialisation of medical devices in the surgical metaverse. i3S: A Porto-Based Hub for Bioengineering Similarly, the Institute for Research and Innovation in Health (i3S) in Porto merges three founding institutes (IBMC, INEB, and IPATIMUP) to face aging, infectious diseases, and regenerative medicine. This integrative nature provides leaders like Bruno Sarmento and Andreia Pereira with access to state-of-the-art facilities and a multidisciplinary team of clinicians and researchers. The "Nanomedicines & Translational Drug Delivery" group at i3S, led by Sarmento, is a testament to how institutional solidity fosters international leadership in complex fields like pharmaceutical nanotechnology. The Investment Landscape: 2025 and Beyond The funding trajectory for Portuguese healthtech in 2025-2026 indicates a shift toward "Endurance and Adoption". While previous years focused on rapid digitisation, the current phase prioritises "sustainable technology" and "clinical validation". The Role of Portugal Ventures and 3xP Global Portugal Ventures, the national venture capital company, remains a foundational supporter, managing a portfolio of 20+ life sciences companies and offering pre-seed funding through initiatives like "Call INNOV-ID". The appointment of new leadership for the 2025-2027 triennium focuses on making the institution a "closer and more agile partner" for health and biotechnology startups. Concurrently, private equity firms like 3xP Global are launching dedicated "Health Innovation Funds". Their investment in BloodFlow highlights a focus on "infrastructure-level solutions" that turn routine diagnostics into real-time decisions.This strategic alignment between institutional support and focused private capital is essential for the global expansion of Portuguese healthtech leaders. Ecosystem Maturation: Regional Hubs and Decentralization The decentralisation of the startup scene is a hallmark of Portugal's maturing ecosystem. While Lisbon and Porto are the primary centres, the growth of cities like Coimbra and Aveiro signals a national trend where innovation is no longer confined to the capital. The Porto-Coimbra-Lisbon Corridor The "Porto Region" saw a significant increase in investment volume in 2025, driven by a mix of early-stage activity and scale-up rounds for companies like PFX Biotech and Immunethep. The Biocant Park in Cantanhede (near Coimbra) has provided the ideal conditions for Immunethep to expand its R&D facilities independently. This regional specialisation, Porto for bioengineering and drug delivery, Lisbon for digital surgery and AI, and the Coimbra region for immunotherapy and vaccines—creates a diversified and resilient national healthtech portfolio. Future Outlook: Indicators of Sustained Leadership As we look toward 2027, the success of these 20 leaders will be measured by their ability to achieve several key benchmarks: Clinical Adoption at Scale: Transitioning from research projects (e.g., MetaBreast) to widely implemented medical devices in everyday clinical practice. Regulatory Clearance (CE-marked and FDA-cleared): Achieving medical device certification is a critical goal for leaders like Tiago Costa (BloodFlow) to become the "invisible standard layer" of diagnostics worldwide. Global Commercial Readiness: For biotech leaders like Ali Osman (PFX Biotech), accelerating the path to commercial launch for allergen-free human milk proteins is the next "defining moment" Successful IPOs and Record Exits: Virgílio Bento’s target of an IPO by 2028 will serve as a bellwether for the entire Portuguese healthtech sector, signalling its ability to produce global health leaders at scale. The Portuguese healthtech and medtech ecosystem is no longer in its infancy. It is characterized by leaders who combine scientific depth with entrepreneurial drive, supported by institutions that prioritize translational impact. The integration of AI, augmented reality and precision biotechnology into the clinical landscape is not just a future possibility, it is a transformation currently being enacted by these 20 leaders. As visibility and reliability outperform novelty, the Lusitanian life sciences sector is positioned for long-term endurance on the global stage. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

20 Future Swiss HealthTech and MedTech Leaders The Macroeconomic and Academic Foundations of Swiss Innovation The Swiss life sciences sector has entered a transformative era in 2025 and 2026, characterised by a fundamental shift from traditional pharmaceutical dominance toward a highly integrated "deep tech" health ecosystem. This evolution is underpinned by a robust venture capital environment that saw high-tech investments rise by 23.9% to CHF 2.9 billion in 2025, despite broader global economic uncertainties and sluggish growth in export-oriented industries. Within this capital influx, the medtech and biotech sectors have emerged as the most resilient pillars, driven by the unparalleled efficiency of the Swiss academic engine, specifically the Swiss Federal Institutes of Technology in Zurich (ETH Zurich) and Lausanne (EPFL). The record-breaking creation of 46 new ventures from ETH Zurich in 2025 serves as a testament to the maturation of the university spin-off model. This model is no longer merely about patent licensing but represents a comprehensive institutional commitment to commercializing research through formalized pathways like the ETH Pioneer Fellowship and the newly launched "Express Licensing" procedure. This procedure, which provides a standardized, negotiation-free license within six to eight weeks in exchange for a modest 2% equity stake, has drastically reduced the barriers to entry for scientific founders. Consequently, Swiss academic institutions now rank among the top ten globally for spin-off value creation, outperforming larger economies on a per-capita basis. However, the ecosystem faces a structural "late-stage gap," where approximately 96% of late-stage capital originates from international sources. This has necessitated a strategic focus on global expansion, particularly into the United States market. The Venture Leaders Medtech program, which selects the "Swiss National Startup Team" for an intensive roadshow in Boston, serves as a critical bridge for these 20 leaders as they transition from pre-clinical prototypes to market-ready clinical solutions. Comparative VC Funding Landscape 2025 The following data illustrates Switzerland's leading position in venture capital efficiency relative to its European peers, highlighting the concentration of capital available for high-growth healthtech ventures. Country VC-Funding (EUR) Inhabitants VC per Capita (EUR) Finland 2,200,000,000 5,621,739 391 Switzerland 3,100,000,000 9,007,798 344 United Kingdom 22,000,000,000 69,931,528 315 Ireland 1,600,000,000 5,356,950 299 Sweden 2,200,000,000 10,701,047 206 Denmark 1,200,000,000 6,023,520 199 Netherlands 3,300,000,000 18,448,775 179 Germany 7,700,000,000 83,644,258 92 The Robotics Renaissance in Interventional Medicine At the forefront of the Swiss medtech revolution is a new generation of surgical robotics companies that leverage soft materials and magnetic control to overcome the physical limitations of traditional rigid instruments. These leaders are addressing high-stakes clinical scenarios, particularly neuro-vascular interventions and complex brain surgeries, where precision at the millimetre scale is non-negotiable. 1. NanoFlex Robotics: Magnetic Navigation for Neurovascular Health NanoFlex Robotics, an ETH Zurich spin-off founded in 2021, represents a paradigm shift in the treatment of stroke and other neuro-vascular diseases. The company's technology is rooted in over 20 years of research from the Multi-Scale Robotics Lab, led by co-founder Bradley Nelson. Under the leadership of CEO Matt Curran, NanoFlex has developed a soft robotic system that enables surgeons to steer specially adapted catheters and guide wires through the intricate vasculature of the brain using remote magnetic fields. The core innovation lies in the transition from manual, friction-dependent catheter manipulation to a magnetic steering system that minimises trauma to the vessel walls. This technology not only simplifies complex procedures but also potentially reduces the radiation exposure for physicians, as the system can be operated from a distance. In 2023, NanoFlex secured USD 12 million in Series A funding, which has facilitated the installation of their first demo systems and the progression toward first-in-human clinical trials. 2. Distalmotion: Democratising Robotic Surgery in Outpatient Settings While giants like Intuitive Surgical dominate the hospital-based soft-tissue robotics market, Distalmotion has identified a critical underserved segment: the Ambulatory Surgery Center (ASC). Their DEXTER® Robotic Surgery System is designed for a high-volume, cost-effective environment, offering a smaller footprint and seamless integration into existing operating rooms. Distalmotion, led by CEO Greg Roche, a medtech veteran with over 20 years of experience, successfully closed a USD 150 million Series G round in 2025. This was followed by a strategic investment from Johnson & Johnson Innovation in early 2026, aimed at accelerating the US adoption of DEXTER for general surgery, gynecology, and urology. The DEXTER system’s unique value proposition is its "hybrid" approach, allowing surgeons to switch between robotic and manual laparoscopic modes instantly, thereby optimizing clinical efficiency in outpatient settings. 3. Clee Medical: Advancing Real-Time Vision in Neurosurgery Clee Medical addresses the "dynamic uncertainty" of the neurosurgical operating room. Traditional neurosurgery relies heavily on static, pre-operative imaging (MRI/CT), which does not account for the "brain shift" that occurs during surgery. Clee Medical’s flagship platform, Neuro Access, integrates ultra-high-resolution real time intra-operative Optical Coherence Tomography (OCT) imaging with AI-powered anatomical navigation. The Geneva-based startup, emerging from the Wyss Center in 2024, is led by CEO Matt Lapinski, who brings extensive experience in building Class III medical device startups in the United States. In early 2026, the company raised seed funding to accelerate its clinical validation program, with the goal of making minimally invasive brain surgery safer and more scalable. Leadership Profile: Surgical Robotics Leader Company Background Strategic Focus Matt Curran NanoFlex Robotics University of Edinburgh; Medical device commercialization Stroke treatment via magnetic soft robotics Greg Roche Distalmotion Sociology and Law; 20+ years in MedTech (Stryker, etc.) ASC expansion and purpose-built robotics Matt Lapinski Clee Medical Engineer; Class III device expert (Medtronic background) Real-time OCT imaging for neurosurgery The Digitalisation of Diagnostics and Preventive Health A major theme in the 2025–2026 cohort is the decentralization of clinical-grade diagnostics, moving specialized testing from centralized hospital labs directly to the point-of-care or even into the patient's home. This trend is powered by sophisticated AI algorithms that democratise expert-level interpretation of medical data. 4. QUMEA: Redefining Patient Safety with Radar-Based AI QUMEA, the winner of the Swiss Medtech Award 2025, has become a benchmark for digital health implementation in institutional care. The company’s technology, developed under CEO Cyrill Gyger, utilizes a contactless 3D radar sensor to monitor patient movement patterns around the clock. Unlike camera-based systems, QUMEA’s approach is entirely anonymous, respecting patient privacy while using AI to analyse movement in real-time. The clinical impact of the system is quantifiable: somatic hospitals implementing QUMEA have reported an average reduction in falls of 74%. This proactively preventative standard of care has led to broad implementation across over 130 institutions in the DACH region and the Nordics. In October 2025, the private equity firm GRO made a strategic investment in QUMEA to accelerate its international expansion, signalling the maturity of the company's business model. 5. Scanvio Medical: AI-Assisted Ultrasound for Endometriosis Scanvio Medical is addressing one of the most significant diagnostic gaps in women's health: endometriosis. Currently, the average delay for an endometriosis diagnosis is 8 to 12 years, primarily because identifying the condition via ultrasound requires rare, high-level expertise. Scanvio, an ETH Zurich spin-off founded in 2024, is developing a real-time AI assistant that guides clinicians through standard pelvic ultrasound examinations to identify signs of the disease. Led by CEO Stefan Tuchschmid—who previously scaled VirtaMed into a global leader in surgical training—Scanvio secured USD 3.4 million in a seed round in 2025. The platform leverages algorithms developed during CTO Dr. Fabian Laumer’s PhD research, aiming to democratise expert-level ultrasound diagnostics for gynaecology practices worldwide. 6. Testmate Health: Democratizing Sexual Health Testing Testmate Health is positioned to tackle the "silent epidemic" of sexually transmitted infections (STIs) by providing a product aligned with urgent public health initiatives. Their diagnostic solution offers a low-barrier, rapid testing platform that can be used outside of traditional clinical settings, encouraging regular screening and faster treatment cycles. By combining molecular diagnostic accuracy with consumer-grade ease of use, Testmate Health represents the vanguard of "home-first" clinical diagnostics in Switzerland. 7. Avelo: Breath-Based Pathogen Collection Avelo is revolutionizing the diagnosis of lower respiratory tract infections through its innovative breath collection device.Traditional methods for diagnosing pneumonia often involve invasive procedures or the collection of sputum, which can be difficult for many patients. Avelo’s hand-held device captures pathogens directly from a patient’s breath, enabling a non-invasive and rapid pathway to identifying the cause of infection. This technology is critical for antimicrobial stewardship, as it allows clinicians to differentiate between viral and bacterial infections at the point-of-care, ensuring that antibiotics are only prescribed when necessary. 8. IMAI MedTech: Automated 3D Histology IMAI MedTech, a Schlieren-based startup founded in 2024 by CEO Francesca Catto and Robert Axelrod, is bringing three-dimensional visualisation to the field of pathology. Conventional histology relies on thin 2D slices of tissue, which can miss critical diagnostic markers and lead to misinterpretation. IMAI has developed an automated platform for fast tissue processing and 3D visualisation, vital for both clinical and research use in oncology diagnostics. The team, which includes CTO Sascha Brun, plans to use their CHF 150,000 Venture Kick award to finalise their hardware prototype and scale AI features for automated cell counting and cancer mass measurement. Key Performance Indicators: Diagnostic Leaders Startup Metric Impact/Result QUMEA Fall Reduction 74% average reduction in falls Scanvio Medical Diagnostic Delay Aims to reduce 8-12 year wait for endometriosis Evismo Network 1,500+ specialists using remote diagnostics IMAI MedTech Market Size Targeting USD 16B histology/cytology market Neuro-technology and the Restoration of Sensation The Swiss neuro-technology sector has moved beyond simple diagnostic tools toward therapeutic devices that interface directly with the nervous system to restore lost functions. These "bio-digital" leaders are combining material science with artificial intelligence to treat disorders ranging from epilepsy to peripheral neuropathy. 9. Neurosoft Bioelectronics: Soft Stretchable Brain Interfaces Neurosoft Bioelectronics is pioneering the use of soft, stretchable materials for neural implants. Led by CEO and co-founder Dr. Nicolas Vachicouras, the company addresses the mismatch between rigid electronic electrodes and the soft tissue of the brain. In February 2025, Neurosoft achieved a major milestone with the successful testing of its high-channel-count interface in human patients during epilepsy surgery at University Medical Center Utrecht. The company's primary focus is the restorative treatment of tinnitus, epilepsy, and other neurological disorders. In early 2026, Neurosoft entered a multiyear partnership with Science Corp, granting them access to a world-class clinical-grade neural engineering platform. This collaboration is expected to aggressively accelerate the clinical adoption and commercial scaling of their pioneering neural data platform. 20 Future Swiss HealthTech and MedTech Leaders 10. MachineMD: Neuro-Ophthalmology via VR and Ocular Biomarkers MachineMD, a Swiss-American medical device company based in Bern, is revolutionizing brain diagnostics using ocular biomarkers. Their platform, Neos, is a VR-based neurodiagnostic tool that enables fast, scalable, and non-invasive brain assessments by tracking eye movements. CEO Dominic Senn leads a team that includes medical director Mathias Abegg and CTO Dominik Brügger. In October 2024, Neos became the first VR headset to obtain EU MDR Class IIa certification for the assessment and diagnosis of ophthalmic and neurological disorders. This certification is a significant enabler for precision medicine, supporting research and diagnosis for people with Parkinson's, multiple sclerosis (MS), and other rare diseases.MachineMD’s technology addresses the shortage of neuro-ophthalmologists by providing highly reproducible, objective data that can be interpreted by a wider range of healthcare professionals. 11. Mynerva: Tactile Restoration for Peripheral Neuropathy Mynerva, an ETH Zurich spin-off, won the Venture Awards Grand Prize in June 2025 for its work in restoring the sense of touch. Led by CEO Greta Preatoni, the company focuses on medical technology for patients suffering from sensory loss, particularly those with diabetic peripheral neuropathy. By providing artificial tactile feedback, Mynerva’s technology helps patients regain balance and reduce the risk of falls, a critical complication of neurodegenerative diseases. 12. Biped Robotics: AI-Powered Mobility for the Visually Impaired Biped Robotics has developed an AI-powered wearable that assists blind and visually impaired individuals in navigating safely in real time. The device uses 3D cameras and spatial audio to identify obstacles and provide directional guidance, essentially acting as a "co-pilot" for human mobility. Ranked 95th in the 2025 Top 100 Swiss Startup Award, Biped represents a broader trend of applying computer vision and edge-AI to enhance the quality of life for those with physical or sensory impairments. Advanced Therapeutics, Vaccines and Bio-Engineering The Swiss life sciences sector continues to push the boundaries of biotechnology, with a specific focus on antibacterial resistance, targeted drug delivery, and orthopedic restoration. These future leaders are leveraging synthetic biology and advanced material science to create treatments that were previously impossible. 13. Baxiva: Leading the Fight Against E. Coli Baxiva, an ETH Zurich spin-off incorporated in 2025, is developing a first-in-class vaccine designed to prevent diseases caused by Escherichia coli (E. coli), such as urinary tract infections. Led by CEO Dr. Giorgia Greter and CSO Dr. Tim Keys, the company combinesScientific innovation in bacterial vaccines with industrial experience in conjugate development. In early 2026, Baxiva joined the CARB-X portfolio, receiving USD 3 million to advance its vaccine candidates toward clinical development. Their multivalent glycoconjugate platform addresses a critical unmet need in infection prevention, offering a viable alternative to the overuse of antibiotics. Baxiva’s success highlights the power of Swiss glycobiology research in addressing global health threats like antimicrobial resistance. 14. Flowbone: Strengthening Bones with Injectable Hydrogels Flowbone addresses the massive public health burden of osteoporosis through its injectable, "bone-seeding" gel. The technology, which provides a local strengthening of fragile bones, is designed to prevent fractures before they occur.Under the leadership of project leaders like Peyman Karami and Valérie Malfroy Camine, Flowbone exemplifies the trend toward "minimally invasive preventative orthopaedics," where early intervention can prevent the catastrophic consequences of hip and spinal fractures in the elderly population. 15. Positrigo: Decentralized Nuclear Imaging for Brain Health Positrigo is democratizing advanced functional brain imaging through its ultra-compact PET system, NeuroLF. Founded in 2018 as an ETH Zurich spin-off by CEO Jannis Fischer and COO Max Ahnen, Positrigo aims to make precision brain scanning available to everyone at a fraction of today's cost. In 2025, the company raised CHF 7 million in a round led by HealthCap to boost production and commercialization. In early 2026, Positrigo was named a finalist for the Swiss Medtech Award 2026. Their "BrainPET Accelerator Program," launched in the US in 2026, enables neurology practices to offer advanced PET imaging directly within their offices, significantly improving access to diagnostics for Alzheimer's disease and other neurodegenerative conditions. 16. Myria Biosciences: GEMMS for Transformative Small-Molecules Myria Biosciences, led by CEO Steven Schmitt, is an ETH Zurich and HZI/HIPS spin-off that pioneers drug discovery through Genetically Engineered Modular Molecule Scaffolds (GEMMS). Their platform integrates high-throughput synthetic biology with AI-driven design to develop therapies that exceed the constraints of nature. Myria represents the "tech-bio" frontier, where synthetic natural products are smartly engineered for biological production, paving the way for next-generation small-molecule therapies. Scientific Leadership Profile: Therapeutics and Bio-Engineering Leader Company Domain Expertise Core Innovation Giorgia Greter Baxiva Microbiology/Vaccines E. coli glycoconjugate vaccine platform Steven Schmitt Myria Biosciences Synthetic Biology GEMMS for AI-driven drug discovery Jannis Fischer Positrigo Particle Physics (ETH PhD) Compact NeuroLF PET system Valérie Malfroy Camine Flowbone Orthopedic Bio-Engineering Injectable "bone-seeding" hydrogel Systems of Care and Structural Medtech Innovation The final group of future leaders focuses on the hardware and software "infrastructure" of healthcare, optimising existing clinical workflows and improving the accuracy of standard surgical procedures. 17. Evismo: Intelligent Remote Diagnostics for the Heart Evismo is a Zurich-based healthtech company that has combined state-of-the-art sensor technology with AI-based software to revolutionise remote cardiac diagnosis. A finalist for the Swiss Medtech Award 2025, Evismo provides a suite of diagnostic services: CardioFlex for cardiac arrhythmias, RespiFlex for sleep apnea, and StressCheck for analyzing stress and burnout. Their model facilitates early detection directly in the general practitioner's practice, ensuring that patients receive timely interventions before condition escalation. 18. Bonebridge: Quality-Driven Musculoskeletal Trauma Solutions Bonebridge focuses on high product quality and ease of clinical application in the field of musculoskeletal trauma. As a finalist for the Swiss Medtech Award 2025, Bonebridge addresses various clinical challenges related to trauma surgery through innovative hardware and a focus on "Swissness" in manufacturing. Their collaborative approach with globally recognised partners ensures that their developments contribute sustainably to the improvement of patient care in high-stress surgical environments. 19. HeroSupport: Personalizing Radiotherapy with 3D Printing HeroSupport, founded in 2023, specializes in patient-specific immobilization for radiation therapy. Their flagship product, VENUS SHELL, is a 3D-printed immobilization shell designed for breast radiotherapy in a prone position. This patient-specific approach ensures that the target tissue is precisely positioned during every treatment session, improving clinical outcomes and patient comfort. HeroSupport was awarded the "most investable startup" title at the Swiss-Italian Startup Award 2025, reflecting the high market interest in personalised oncology support tools. 20. PeriVision: AI-Driven Visual Function Assessment PeriVision, ranked 69th in the 2025 Top 100 Swiss Startup Award, combines AI, VR, and cloud technology to build next-generation systems for understanding visual function. Their solution allows for the fast and objective assessment of the visual field, which is critical for monitoring chronic conditions like glaucoma. By utilising portable VR headsets, PeriVision enables testing outside of the traditional darkened clinical room, making diagnostic screening more accessible and efficient for both patients and providers. The Future Roadmap for Swiss Medtech and HealthTech As the Swiss ecosystem moves toward 2030, several macro-trends will define the success of these 20 leaders. The first is the integration of "Foundation Models" and "Multimodal AI" into clinical workflows. This involves combining electronic health records (EHR), medical imaging, and sensor data from wearables like those of QUMEA or feedback intuitive to provide a holistic, predictive view of patient health. Secondly, the "Late-Stage Gap" will continue to drive M&A activity. The acquisitions of Araris Biotech for USD 1.1 billion and OBaris by Johnson & Johnson in 2025 serve as a powerful validation of the Swiss academic spin-off model, yet also highlight the reality that most Swiss high-tech ventures will ultimately be scaled by international giants. Finally, the focus on "Modernizing the Mechanics of Care" will remain a priority. This includes the rollout of digital hospitals and smart infrastructure, such as the smart hospital platforms being developed by Stryker and others, which will serve as the host environment for many of the Swiss robotic and AI innovations discussed. Anticipated Milestones (2026–2030) Year Company Milestone Type Description 2026 Positrigo Award/Finalist Swiss Medtech Award Ceremony (June 10, 2026) 2026 Clee Medical Clinical Initiation of first-in-human neurosurgery studies 2026 Distalmotion Regulatory Expected FDA gynecology/general surgery expansion 2026 Baxiva Preclinical Advance vaccine project toward clinical phase with CARB-X 2027 Roche Regulatory Planned filing for afimkibart (bowel disease) Conclusion: Synthesising the 2025-2026 Swiss Leadership The 20 future leaders profiled in this report represent a sophisticated synthesis of Switzerland’s long-standing excellence in precision engineering and its rapid ascent in the fields of artificial intelligence and biotechnology. The recurring theme across these companies, whether in the soft robotics of NanoFlex, the AI-diagnostics of Scanvio, or the glycobiology of Baxiva, is the translation of deep scientific insight into tangible patient benefit. The robust support system provided by institutions like ETH Zurich, EPFL, Venturelab, and Venture Kick has created a uniquely reliable signal for global investors. While the path to global scale often leads through the United States, as evidenced by the 2025 Venture Leaders Medtech Boston roadshow, the intellectual and technological "Swissness" of these ventures remains their primary competitive advantage. By 2030, the innovations of these 20 companies are poised to be integrated into the standard of care worldwide, solidifying Switzerland’s position as a global epicentre for the future of healthcare. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Biological Intelligence: Strategic Rationale for Anthropic's Acquisition of Coefficient Bio The $400 Million Inflection Point: A New Era in Vertical Artificial Intelligence The acquisition of Coefficient Bio by Anthropic in April 2026, valued at slightly more than $400 Million in an all stock transaction, represents a fundamental shift in the strategic deployment of frontier artificial intelligence. While the acquisition involves a team of fewer than ten people, translating to a valuation of approximately $40 Million to $44 Million per employee, the transaction’s importance transcends typical talent acquisition metrics. This move marks Anthropic’s decisive transition from providing horizontal reasoning tools to internalising vertical, biology native generative modeling capabilities. Against the backdrop of Anthropic’s $380 Billion post money valuation established in its February 2026 Series G round, the acquisition represents a calculated 0.1% dilution to secure a cornerstone in the $100 Billion-plus drug discovery market. The deal signals that the race for artificial general intelligence (AGI) has entered a new phase: the conquest of specialised scientific domains where general-purpose models previously acted as mere assistants. By absorbing Coefficient Bio, Anthropic is not merely buying a startup; it is integrating a specific "reasoning density" focused on the discrete mathematical challenges of molecular biology. This acquisition allows Anthropic to challenge the established dominance of Alphabet’s Isomorphic Labs and the capital-heavy Xaira Therapeutics by providing a differentiated approach to biological discovery based on "Discrete Walk Jump Sampling" (dWJS), a methodology that bridges the gap between digital prediction and physical synthesis. The Transaction and Organisational Integration The deal closed on April 3rd, 2026, during a period of intense consolidation and M&A activity within the AI sector. The entirety of the Coefficient Bio team is slated to join Anthropic’s Health Care and Life Sciences division, a group led by Eric Kauderer-Abrams. Kauderer-Abrams, an industry veteran hired in mid 2025 after leading a diagnostics firm focused on nucleic acid detection, has been tasked with an explicit mandate: to make Claude the dominant AI model for the biological sciences. Key Transaction Metric Detail Source Total Valuation Approximately $400,000,000+ Various Transaction Structure All-stock buyout Various Effective Date April 3rd, 2026 Various Acquired Personnel <10 Employees Various Dilution (Anthropic) ~0.1% based on $380 Bn valuation Various Strategic Lead Eric Kauderer-Abrams Various The Genesis of Coefficient Bio: The Prescient Design Exodus Coefficient Bio emerged from a unique juncture in the biopharmaceutical industry. In early 2025, Roche’s Genentech unit underwent a significant restructuring, eliminating 489 roles as the organisation sought to reorient itself toward "embedding digital, automation, and AI capabilities" throughout its pipeline. This transition inadvertently triggered a talent exodus from Prescient Design, Genentech’s elite computational drug discovery unit. Among those departing were Samuel Stanton and Nathan C. Frey, who founded Coefficient Bio in August 2025. Founding Team and Scientific Pedigree The founders represent a rare fusion of machine learning expertise and deep biological intuition, a combination that has become the most sought-after commodity in the 2026 technology landscape. Nathan C. Frey, who served as Coefficient's Chief Technology Officer, holds a PhD in materials science and engineering from the University of Pennsylvania. At Prescient Design, he led a multidisciplinary team of ML scientists, molecular biologists, and engineers, setting the roadmap for biological foundation models and establishing critical collaborations with NVIDIA on the BioNeMo platform. His publication record includes high-impact work in Science Advances and Nature Machine Intelligence, culminating in an ICLR 2024 Outstanding Paper Award for "Protein Discovery with Discrete Walk-Jump Sampling". Samuel Stanton, a principal ML scientist at Coefficient and formerly at Prescient Design, holds a PhD in data science from New York University. He was a key architect of biological deep learning libraries at Genentech, including "Cortex," a modular architecture for drug discovery, and "Beignet," an open-source standard for molecular representation. Stanton’s recruiting pitch in early 2026, "ushering biopharma into the Intelligence Age", reflected a vision of the industry where AI does not just assist research but fundamentally dictates how the industry learns and makes decisions. Aris Theologis, Coefficient’s CEO and co-founder, provided the business strategy necessary for such a rapid exit. An MBA graduate from Harvard Business School with a background in biochemistry and biophysics from Stanford, Theologis was previously a founding team member and Chief Business Officer at Evozyne. During his tenure there, he secured over $150 Million in capital and established partnerships with Takeda and NVIDIA, demonstrating a proven ability to bridge the gap between "stealth" research and commercial viability. The Role of Dimension and the 38,000 Percent Return The rapid success of Coefficient Bio was facilitated by Dimension, a New York-based venture capital firm founded in 2023 by former partners of Lux Capital and Obvious Ventures, Adam Goulburn, Zavain Dar and Nan Li. Dimension, which focuses exclusively on the intersection of technology and life sciences, held approximately half of Coefficient Bio prior to the acquisition. The firm’s investment thesis is built on the conviction that the "agentic AI wave" will hit life sciences as forcefully as it has impacted software engineering. By backing the Coefficient team at a near zero basis during its stealth phase, Dimension reported an internal rate of return (IRR) of 38,513%. While this astronomical figure reflects the current "repricing" of early-stage science bets in the AI era, it also validates the firm’s strategy of identifying elite researchers before they leave legacy institutions. Founder/Lead Background Prior Projects/Roles Source Aris Theologis (CEO) HBS MBA, Stanford BS CBO at Evozyne, Paragon Biosciences Various Nathan C. Frey (CTO) PhD (UPenn), Materials Science Group Leader at Prescient Design (Genentech) Various Samuel Stanton PhD (NYU), Data Science Principal ML Scientist at Prescient Design Various Eric Kauderer-Abrams Diagnostics/HCLS Vet Head of Biology and Life Sciences (Anthropic) Various Technical Core: Discrete Walk Jump Sampling (dWJS) The primary strategic driver of the acquisition is the dWJS framework, which resolves long-standing difficulties in training and sampling from discrete generative models for biological sequences. Biological data, unlike the continuous pixel data of images, is fundamentally discrete; a single amino acid substitution can entirely negate a protein’s function. Empirical Performance and the Distributional Conformity Score A critical component of the dWJS research was the introduction of the Distributional Conformity Score (DCS), a scalar metric used to benchmark protein generative models. In validation studies focused on antibody design, the Coefficient founders demonstrated that by optimising for DCS, 97-100% of generated samples were successfully expressed and purified in a single round of synthesis. Furthermore, 70% of these functional designs showed equal or improved binding affinity compared to known functional antibodies on the first attempt. This level of precision is essential for Anthropic’s "lab-in-the-loop" vision, where the AI doesn't just suggest possibilities but provides "wet-lab ready" candidates with high probability of success. The dWJS approach outperformed autoregressive models, masked protein language models and standard diffusion baselines in ab initio protein discovery. Anthropic’s Strategic Roadmap: From Assistant to Scientist The acquisition of Coefficient Bio is the second major phase of Anthropic’s healthcare and life sciences strategy, which has evolved rapidly since mid-2025. Until now, Anthropic’s approach centred on adapting its general-purpose Claude models for scientific workflows. Phase I: The "Claude for Life Sciences" Ecosystem Launched in October 2025, Claude for Life Sciences was designed as a research partner embedded in existing scientific environments. This offering focused on "connectors" that linked Claude to industry-standard tools. Connector Function in Life Sciences Source Benchling Links Claude to source experiments, notebooks, and SOPs Various BioRender Accesses library of vetted scientific figures and templates Various PubMed Natural language search of 35M+ biomedical articles Various Synapse.org Collaborative data sharing and analysis for private projects Various 10x Genomics Conducts single-cell and spatial analysis via natural language Various Medidata Integration with clinical trial data and operational workflows Various ClinicalTrials.gov Assists in trial planning and regulatory strategy Various This phase demonstrated immediate value. Novo Nordisk reportedly used Claude to reduce clinical documentation timelines from ten weeks to ten minutes, fundamentally changing how medicines move from discovery to patients.However, this model remained an "assistant" that automated administrative and analytical tasks rather than a "scientist" that proposed new biology. Phase II: Internalising Biology Native Models The Coefficient Bio acquisition signals the shift from adapting general models to building biology-native AI. Rather than using Claude to summarize a paper about a protein, Anthropic is integrating a team capable of building specialised models from the architecture level up, models that "speak" the language of biomolecules as natively as Claude speaks English. Kauderer-Abrams has laid out a three-part roadmap for this phase: Skills Spanning Discovery to Commercialization: Ensuring models have expertise in early-stage discovery, translational research, and clinical operations. Autonomous Scientific Agents: Moving toward "Agent Teams" that can collaborate on complex tasks like drafting R&D plans and managing regulatory strategies. Closed-Loop Experimentation: Integrating virtual simulations with physical labs—often called "lab-in-the-loop"—where the AI proposes experiments, analyzes the results, and iterates autonomously. Biological Intelligence: Strategic Rationale for Anthropic's Acquisition of Coefficient Bio Competitive Landscape: The Arms Race for Biopharma Dominance Anthropic is not entering a vacuum. The 2026 landscape is defined by massive capital deployment from both big tech and venture-backed "AI-native biotechs". Isomorphic Labs (Alphabet/DeepMind) Isomorphic Labs, a Google DeepMind spinoff, is Alphabet’s flagship bet on biological AI. Built on the foundation of AlphaFold 3, which can predict interactions between proteins, DNA, RNA, and small molecules at atomic resolution, Isomorphic treats biology as an information processing problem. In early 2025, Isomorphic secured $600 Million in external funding and announced partnerships with Eli Lilly and Novartis worth nearly $3 Billion. Their strategy is increasingly clinical, with their first AI-designed drug candidates entering human trials by the end of 2026. Xaira Therapeutics Xaira Therapeutics represents the "full-stack" AI-native pharma model. Launched with a record $1 Billion Series A round in 2024, Xaira leverages models like RFdiffusion and RFantibody from David Baker’s lab to design novel proteins from scratch. Unlike Anthropic, which is primarily a model builder, Xaira is building its own therapeutic pipeline, aiming to own the intellectual property of the drugs it discovers. OpenAI and the Moderna Strategic Alliance OpenAI has taken a collaborative approach, most notably through its partnership with Moderna to speed the development of personalised cancer vaccines. OpenAI has also launched specialised tools like "HealthBench" to evaluate AI models in healthcare settings and "ChatGPT Health," which connects users' medical records with the chatbot for personalised insights. Feature Isomorphic Labs Xaira Therapeutics Anthropic (Post-Acq) Source Model Origin AlphaFold 3 (DeepMind) RFdiffusion (Baker Lab) Claude 4.6 + dWJS Various Strategy Pharma Partnerships Internal Drug Pipeline Platform/Agent Infrastructure Various Recent Funding $600M Series A $1B Series A $30B Series G (Anthropic) Various Primary Strength Structural Prediction De Novo Protein Design Reasoning/Agent Coordination Various Geopolitical and Regulatory Turbulence: The HHS Ban The strategic necessity of the Coefficient acquisition is further highlighted by the shifting regulatory environment in the United States. In March 2026, the Department of Health and Human Services (HHS) officially banned employees from using Anthropic’s Claude tool. This decision followed President Donald Trump’s declaration of Anthropic as a "supply chain risk" after the company and the Department of Defense failed to reach an agreement on the agency’s "unfettered access" to its models. Impact on the FDA and Project Elsa The ban has significant implications for the FDA’s drug review process. In 2025, the regulator launched "Elsa," an AI tool designed to accelerate the review of new drug applications. Elsa was originally developed based on Claude and the federal ban has forced the agency to transition to other approved solutions like OpenAI’s ChatGPT Enterprise and Google Gemini. The "America AI Act" and Future Liability The broader legislative context includes the "Trump America AI Act," which proposes a fundamentally new liability framework for AI deployment. Key provisions include: Mandatory Bias Audits: Section 801 requires audits to detect viewpoint discrimination, a requirement that layers onto existing FDA expectations for AI/ML device performance across demographic subgroups. Liability Exposure: The Act creates a statutory duty to prevent foreseeable harm, which must be integrated with existing medical malpractice and HIPAA risk management programs. Digital Replica Protections: Establishing rights for individuals to control the use of their digital likeness, affecting how patient images and biometric data are used in AI development. By acquiring Coefficient Bio and focusing on "fundamental science" and "molecule design," Anthropic may be positioning itself to operate in a domain where the AI’s output is a physical drug candidate, a product subject to traditional pharmaceutical regulation, rather than a chatbot subject to contentious "supply chain" or "viewpoint" scrutiny. The $100 Billion Opportunity: Market Dynamics and the IPO Horizon The acquisition comes as Anthropic prepares for a widely anticipated IPO as early as October 2026. The company’s revenue is projected to exceed $19 Billion in 2026, driven largely by enterprise accounts rather than consumer adoption. Shifting from "Service" to "Native" The biotech industry is moving away from "AI service providers" toward "AI-native biotech companies". Instead of licensing algorithms alone, companies are building proprietary pipelines. For Anthropic, the Coefficient Bio deal allows it to offer "Specialised Tools" that pharmaceutical companies are willing to pay enterprise prices for. This is particularly relevant in oncology, where the complexity of tumour biology and the high cost of failure make AI intervention at every stage, from target identification to regulatory planning, a strategic necessity. The J.P. Morgan Healthcare Conference Insights Discussions at the January 2026 J.P. Morgan Healthcare Conference highlighted that "capital concentration" is a permanent shift in the life sciences. Investors are focusing less on "platform narratives" and more on "tangible clinical proof". M&A activity is on the upswing, driven by the "patent cliff" where brand-name drugs are set to expire, forcing major pharma players to bolster their pipelines through acquisitions. Anthropic’s acquisition of Coefficient Bio mirrors this "bolt-on" strategy, providing a de-risked technological advantage that can be immediately integrated into revenue-generating workflows. Sector Metric Value/Forecast (2026-2034) Source Anthropic Annualized Revenue $19.00 Billion (2026) Various AI in Pharma Market $16.49 Billion (2034) Various Gen AI in Drug Discovery $2.85 Billion (2034) Various Median Bio-AI Valuation $220M - $320M Various Top Bio-AI Valuation (Xaira) $5.0B - $6.5B Various Strategic Logic: Reasoning Density, Not Just Molecules The most nuanced read of the Anthropic-Coefficient deal is that it is an investment in "reasoning density" for regulated scientific work. Drug development is not only bottlenecked by the discovery of new molecules; it is equally hindered by "messy, cross-functional judgment". Compressing the Decision Loop Coefficient’s team, with its background in autonomous scientific agents and probabilistic modeling, is uniquely suited to solve the "decision latency" that plagues biopharma. By integrating dWJS with Claude’s reasoning capabilities, Anthropic can automate: Target Triage: Identifying which biological targets are most likely to yield successful therapies. Protocol Design: Drafting and optimizing study protocols and standard operating procedures. Evidence Synthesis: Managing the interpretation of diverse assays and preparing clinical regulatory submissions. This is a defensive and offensive market play. While "AI discovers drugs" makes for a compelling headline, the larger and more defensible market is the "compression of the decision loop" around science. Whichever foundation model becomes embedded in these R&D workflows will capture a massive, recurring revenue stream. Conclusion: The Path Toward Superintelligence for Science The acquisition of Coefficient Bio for $400 Million is a definitive statement about Anthropic’s vision for the future of artificial intelligence. By absorbing the elite team from Genentech’s Prescient Design unit, Anthropic has moved beyond the "Smart Chatbot" era and into the realm of "Artificial Superintelligence for Science". The integration of Discrete Walk-Jump Sampling provides Anthropic with a unique mathematical edge in the discrete space of biological sequences, enabling the generation of functional, biophysically valid proteins with unprecedented accuracy. This capability, when combined with Claude’s existing enterprise reasoning and agentic coordination, positions Anthropic to solve the "grunt work" of science, the administrative leakage, the decision latency and the high failure rates that have historically defined the pharmaceutical industry. While significant risks remain, including a federal ban on Claude tools and intense competition from Alphabet and Xaira, the acquisition represents a strategically low-cost entry into a domain with long-term platform potential. For Anthropic, the gamble is clear: the next great breakthrough in AI won't be a better poem or a cleaner line of code, but a life-saving medicine discovered through the autonomous collaboration of agentic systems and biology-native foundation models. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Ghent, Porto, Wroclaw: Future European HealthTech and MedTech Hubs The European medical technology and healthcare innovation landscape is currently traversing a period of profound structural realignment, characterised by a transition from speculative digital fragmentation toward a model of industrial maturity and regulatory rigor. As the global MedTech market is projected to expand from a valuation of $549.5 Billion in 2025 to approximately $853.4 Billion by 2035, growing at a compound annual growth rate (CAGR) of 4.5%, the European theatre is emerging as a critical frontier for high-conviction investment and clinical validation. This transformation is driven by a convergence of high medical trend rates, which are expected to reach 11.68% globally in 2025, and a persistent workforce crisis that has seen burnout rates among medical staff climb to 63% in regions like Spain and 36% in France. Consequently, three specific European hubs, Ghent in Belgium, Porto in Portugal, and Wroclaw in Poland are manifesting as primary centres of excellence, leveraging unique combinations of institutional heritage, sovereign funding and technological specialisations in robotics, genomic data and artificial intelligence (AI). The broader European life sciences sector entered 2026 with renewed optimism, supported by a significant rebound in venture capital (VC) investment. In the first half of 2025, global MedTech funding reached $15.4 Billion, a 13% increase from the previous year, signalling a stabilisation of investor appetite after a period of correction. Within Europe, healthcare and life sciences VC volumes reached €13.22 Billion in 2025, representing a 2.8% year-on-year increase. This capital deployment is increasingly governed by "industrial logic," wherein value is derived from operational leverage and clinical utility rather than theoretical scalability. Investors are prioritising "high-conviction bets" on companies with validated clinical data and clear pathways to reimbursement, particularly in the digital health sector, which rebounded to $7.9 Billion globally in H1 2025. The market is bifurcating between established giants and emerging specialized clusters. While the United States continues to dominate nearly 80% of global MedTech venture capital, Europe’s 15–20% share is becoming more concentrated in hubs that can navigate the "Regulatory Darwinism" imposed by the EU Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR). These regulations, while administratively burdensome, are creating a "compliance moat" for firms capable of securing certification, effectively transforming regulatory status into a primary valuation driver. Macro-Economic Determinants and the Regulatory Landscape The implementation of the EU MDR and IVDR frameworks has fundamentally altered the competitive dynamics of the European HealthTech sector. As of 2025, the certification process remains a significant bottleneck, with over 28,000 MDR applications filed but only 12,000 certificates issued; approximately 60% of cases require 13 to 18 months for completion. This environment favors hubs with robust institutional support and dedicated regulatory consulting infrastructure. From May 28, 2026, the mandatory adoption of the European Databank on Medical Devices (EUDAMED) modules, specifically for Actor Registration and Notified Body Certificates, will further formalize transparency. This regulatory convergence acts as a filter, distinguishing "investable assets" from "distressed liabilities" based on their ability to meet stringent data governance and human oversight standards required by the EU AI Act. Companies that successfully operationalise these requirements are finding they can command higher valuation multiples, as they are viewed as lower-risk entries for large-scale acquisitions by pharmaceutical and MedTech incumbents seeking to fill their innovation pipelines. The financial health of the sector is also influenced by the "Dry Powder Paradox." While private equity and venture capital funds hold nearly $2.5 Trillion in unallocated capital, deployment is highly selective, favouring platforms that demonstrate industrial logic over theoretical potential. The investment logic has shifted from "venture subsidies" to "industrial logic," where value is created through operational leverage, vertical integration, and the arbitrage of fragmented markets. European MedTech and Digital Health Market Forecasts (2025–2030) Sector / Region Value (2025 Projected) Value (2030 Projected) CAGR (%) Global MedTech Market $549.5 Billion $685.2 Billion 4.5% European MedTech Market £125.4 Billion £155.2 Billion 4.4% UK MedTech Market £15.7 Billion £20.5 Billion 5.4% European Digital Health — — 22.3% European Digital MSK $1.22 Billion $3.28 Billion 18.1% Hub 1: Tech Lane Ghent > The Benelux Axis of BioTechnical Integration Ghent, Belgium, has solidified its position as a premier European Life Sciences hub, primarily through the concentrated development of Tech Lane Ghent Science Park. This 52-hectare ecosystem hosts over 60 research-oriented companies and is the focal point for 79% of all VC funding in Belgium as of 2025. The hub’s strategy relies on the seamless integration of academic research from Ghent University (UGent) and the Flemish Institute of Biotechnology (VIB) with commercial scaling capabilities. Infrastructure Pipeline and Expansion (2026–2029) The growth trajectory of Tech Lane Ghent is supported by a massive infrastructure pipeline designed to accommodate the transition from early-stage research to industrial manufacturing. The Science Park is divided into two main zones, Zwijnaarde and Ardoyen, which collectively host a range of specialised facilities including the VIB Bio-Incubator and the Obelisc Bio-Accelerator. Project Name Location Estimated Completion Facility Type / Scale Nobel I Building (UZ Gent) Ghent South 2026 18,000 sq m Lab & Office Kadans & PMV Life Sciences Hub Tech Lane 2026 (Phased) 20,000 sq m Lab & Office Plus Ultra Gent Tech Lane 2027 20,000 sq m Multi-tenant AI Campus Hub - The Brain Campus Ardoyen 2027 20,000 sq m AI/Photonics Legend Biotech & J&J Expansion Tech Lane / Obelisc 2028 15,000 sq m CAR-T Mfg New Central Hospital (Project U) UZ Gent 2029 133,000 sq m Clinical UGent Chemistry Campus S11 De Sterre 2029 12,000 sq m Research Strategic Advantage: The ARC Innovation Hub and Clinical Testing A distinctive feature of the Ghent ecosystem is the ARC Innovation Hub, launched in 2025 at AZ Maria Middelares. This facility provides a direct "test-bed" environment, allowing HealthTech startups to validate their solutions in real-world hospital settings. This translational capability is vital for meeting the clinical evidence requirements of the MDR and the newer European Health Technology Assessment (HTA) framework, which became fully operational in 2026. By reducing the gap between prototype development and clinical adoption, Ghent facilitates a faster time-to-market for medical devices and digital tools. The hub also benefits from the presence of UZ Gent (Ghent University Hospital), which acts as a key player for MedTech validation and clinical research. The upcoming Project U, a massive 133,000 square meter development scheduled for 2029, will further enhance the city's capacity for complex clinical trials and patient-centric innovation. Financial and Regulatory Incentives in Flanders The Ghent hub's potential is significantly bolstered by the Flemish government's aggressive R&D support. Flanders Innovation & Entrepreneurship (VLAIO) provides substantial grants for research and development projects, while the fiscal landscape includes an 85% innovation income deduction, effectively lowering the corporate tax rate for net innovation income. Incentive Type Mechanism Target Group Innovation Income Deduction (IID) 85% net income exemption IP-owning firms R&D Payroll Tax Exemption 80% withholding tax recovery Research staff R&D Investment Deduction 13.5% (one-time) or 20.5% (staggered) Capital expenditures Special Tax Status Tax-free allowances (max 30% salary) Inpatriate researchers Young Innovative Company (YIC) Full suite of tax credits Startups under 10 years These measures are designed to ensure that Belgium remains competitive despite the implementation of global minimum tax standards (Pillar 2). For instance, as of 2025, Belgian companies can opt to convert unused innovation income deductions into non-refundable tax credits that can be carried forward indefinitely, maintaining an effective tax rate above the 15% minimum while preserving the long-term tax advantage. Hub 2: Porto > The Southern European Vanguard of Digital Health Porto, Portugal, is emerging as a "growth frontier" for European HealthTech, characterised by a highly skilled workforce and a robust pipeline of university spin-outs. The city’s ecosystem value reached $7.5 Billion by late 2024, with a CAGR of 48%, a metric that significantly outperforms the global average of -14% during the same period. Porto’s development is anchored by the University of Porto’s Science and Technology Park (UPTEC) and the ScaleUp Porto initiative, which facilitates collaboration between founders and international investors. Workforce Dynamics and Talent Pipeline Portugal’s MedTech workforce reached 12,800 professionals in 2024, accounting for 31% of the industry's total employment base. This sector is projected to expand at a CAGR of 6.1%, reaching 18,200 professionals by 2030. Porto specifically accounts for a significant portion of this growth, offering a competitive talent-to-cost ratio that attracts both multinational corporations and high-growth startups. Workforce Segment Share of Industry (%) Primary Function Engineering & Platform 42 Software Development / MDR Compliance Data & AI Professionals 28 Clinical Analytics / Predictive Modeling Cybersecurity Specialists 18 Data Privacy / NIS2 Implementation Product & Experience 12 UX Design / Regulatory UX Sovereign Investment and PRR Funding The Portuguese government’s commitment to digital transformation is a primary catalyst for Porto’s potential. Under the Plano de Recuperação e Resiliência (PRR), nearly €890 million is dedicated specifically to healthcare technology and Industry 4.0 adoption. These funds are being used to modernise legacy health systems, integrate artificial intelligence into diagnostic workflows, and ensure compliance with the MDR framework. Furthermore, the 2024 reorganisation of the National Health Service (SNS) into 39 Local Health Units (ULS) has created a unified procurement environment that favours interoperable digital solutions. Major public hospital projects are underway, including the New Hospital of the West and expansion at Trofa Saúde Maia, which serve as potential integration sites for local HealthTech innovations. Strategic Growth Metrics for Porto (2024–2025) The investment landscape in Porto has shown remarkable resilience. From 2024 to 2025, Porto experienced a 51% increase in total VC funding and a 163% increase in the median seed round, which now stands at $1 Million. Metric Value (2024/2025) Global Benchmark Comparison Ecosystem Value $7.5 Billion High Growth Tier Median Seed Round $1.0 Million 163% Increase YoY Median Series A Round $6.4 Million Maturing Hub Status Software Engineer Salary (Avg) $33,000 Top 20 Affordable Talent (EU) Total Early-Stage Funding $129 Million (H2 2022 – 2024) The presence of technology centres for eight unicorns, including Revolut, Anchorage Digital, and Feedzai, underscores Porto's appeal as a hub for secure, scalable technology. The hub's focus on "Vertical AI" with robust governance is particularly relevant as investors in 2026 increasingly avoid "Black Box" models in favor of transparent, clinically validated algorithms. Ghent, Porto, Wroclaw: Future European HealthTech and MedTech Hubs Hub 3: Wroclaw > The Central European Axis of Genomic Sovereignty Wroclaw, Poland, often referred to as the "Polish Silicon Valley," has emerged as a top-tier MedTech hub, ranking 16th globally in the sector. The city’s innovation engine is the Wroclaw Technology Park (WPT), the largest of its kind in Poland, which hosts over 200 companies and provides a specialised ecosystem for R&D, MedTech, and advanced engineering. The primary catalyst for Wroclaw’s massive potential in the next 2 to 3 years is the formation of the Wroclaw BioTech Hub, an initiative that consolidated seven major scientific institutions in February 2025. Genomic Infrastructure and the G4PL Project A cornerstone of Wroclaw’s 2026–2029 outlook is the G4PL (Genomics for Poland) project. With a total value of approximately PLN 248.3 Million (approx. €57 Million), the project aims to establish a nationwide, interoperable genomic infrastructure. This infrastructure addresses a critical gap in the Polish R&D landscape by enabling high-throughput sequencing and the storage of genomic data in compliance with FAIR (Findable, Accessible, Interoperable, Reusable) principles and GDPR. Project Aspect G4PL Detail Implementation Timeline Total Project Value PLN 248,337,770 2026 – 2029 Total External Funding PLN 180,481,656 Phased Disbursement Łukasiewicz – PORT Share PLN 11,026,039 Focused on Genomic Platform Primary Objective Genomic Data Sovereignty Alignment with EU 1+MG Secondary Objective Personalized Medicine Precision Oncology Focus By creating a well-characterised population dataset, Wroclaw is positioning itself as an essential partner for pan-European initiatives such as the European Excellence Hub. This "data plumbing" is expected to unlock significant value in oncology and rare disease research, areas where Wroclaw-based firms like Genomtec and Pure Biologics are already established. Institutional Synergy: Łukasiewicz – PORT and the BioTech Hub The Łukasiewicz Research Network – PORT (Polish Center for Technology Development) serves as the hub’s initiator and coordinator. In 2026, PORT received substantial funding for the modernisation of clean room facilities and the expansion of laser infrastructure, totalling PLN 63.2 million. These upgrades are intended to support the development of semiconductor components and micro-nanostructuring of materials, which are increasingly vital for next-generation medical sensors and intelligent surgical robotics. The Wroclaw BioTech Hub integrates the efforts of seven major institutions: University of Wrocław Wrocław University of Science and Technology Wrocław University of Environmental and Life Sciences Wrocław Medical University Institute of Immunology and Experimental Therapy, Polish Academy of Sciences Institute of Low Temperature and Structure Research, Polish Academy of Sciences Łukasiewicz – PORT (Coordinator). This consolidation allows Wroclaw to enter large international research consortia and lead ambitious projects that no single institution could achieve alone. The hub's focus on personalised medicine and the early detection of cancer aligns with the "Safe Hearts Plan" and other EU-wide health priorities. VC Investment and Startup Maturation in Poland (2025–2026) The Polish VC market in 2025 was characterized by capital concentrating in globally competitive companies. Total VC investment reached €0.8 billion across 183 transactions, with healthcare remaining the leading sector for the sixth consecutive year, accounting for 13.1% of all completed transactions. Investment Trend 2025 Metric Significance for Hub Growth Total VC Flow €797 Million Maturing Market Foundation Seed Stage Transactions 134 Deals 20% Increase YoY Avg Seed Ticket Size €1.5 Million Stability for Risk-Taking Healthcare Sector Share 13.1% Continued Dominance Biotechnology Deals 11 Rounds > €20M Scale-up Momentum Wroclaw's position is further strengthened by its ranking as the 16th globally in MedTech and 33rd in the Global Startup Ecosystem Index. The presence of global players such as Siemens Healthineers, combined with high-growth local startups like Biocam (capsule endoscopy) and Biotts (drug delivery), creates a balanced ecosystem of innovation and commercialisation. Technological Convergence: The Drivers of Innovation (2027–2029) The potential of these three hubs is underpinned by the convergence of several high-growth technological sectors. Medical devices and digital health solutions are no longer discrete categories; they are merging into interoperable ecosystems that prioritise patient-centric outcomes. Agentic AI and Patient Twinning Agentic AI, systems capable of autonomous decision-making and task execution, is projected to significantly impact MedTech by 2026. Approximately 30% of industry leaders identified agentic AI as an influential trend, signaling a shift from simple diagnostics to predictive, real-time clinical intervention. These systems can function as collaborators, freeing 25% to 40% of enterprise capacity and capturing incremental growth by linking discovery to commercialisation with unprecedented speed. The application of "patient twinning", creating digital replicas of individuals to simulate treatment outcomes, is becoming a cornerstone of personalised therapy. Siemens Healthineers (Germany), with its strong presence in hubs like Wroclaw and Porto, is a leader in this space, using AI-driven imaging and analytics to transform cancer diagnostics and chronic disease management. Robotic Surgery and Modular Ecosystems The surgical robotics market is maturing with the entry of modular systems that challenge the historical dominance of established players. CMR Surgical (UK), with its Versius Plus platform, has targeted an installed base of over 1,000 systems by 2026, supported by a new manufacturing facility capable of producing 500 systems annually. In France, Moon Surgical is utilizing NVIDIA AI integration for its Maestro collaborative robotics system, targeting the high-growth ambulatory surgical center (ASC) market. Ghent's Tech Lane Science Park, through its proximity to leading surgical units at UZ Gent and AZ Maria Middelares, provides the ideal environment for the testing and validation of these modular robotic systems. The Evolution of Medical Grade Wearables The wearable technology sector has transitioned from consumer-grade fitness tracking to medical-grade diagnostic monitoring. Oura (Finland), valued at $11 billion in late 2025, exemplifies this shift by moving into holistic health platforms that integrate with formal healthcare systems. In Porto, Sword Health’s integration of wearable sensors with AI-driven computer vision represents the future of home-based rehabilitation and musculoskeletal care. This "AI Care" model allows clinical expertise to scale without the high headcount costs of traditional clinics, addressing the workforce crisis that currently plagues European healthcare systems. Comparative Strategic Indicators (2026–2029) The following table provides a high-level comparison of the strategic indicators for Ghent, Porto and Wroclaw, reflecting their developmental trajectory and potential for the next 2 to 3 years. Hub Feature Tech Lane Ghent (Belgium) Porto Ecosystem (Portugal) Wroclaw BioTech Hub (Poland) Primary Specialisation CAR-T / Advanced Biologics AI-Driven Virtual Care Genomics / MedTech R&D Key Infrastructure Plus Ultra / Project U UPTEC / ScaleUp Porto WPT / G4PL Infrastructure Govt Funding / Incentives VLAIO Grants / IID (85%) PRR (€890M) / R&D Tax (12-15%) FENG Funding / EIC Awards VC Momentum (2025) 79% of National VC 51% Increase in VC €0.8B Market Value Workforce Dynamics High-Skill Research Base 18,200 Professionals by 2030 78,000 Tech Talent Base Clinical Validation ARC Innovation Hub SNS/ULS Unified Market Wroclaw Medical Univ / PORT Strategic Implications and Future Outlook The evolution of Ghent, Porto, and Wroclaw as primary HealthTech and MedTech hubs suggests a broader shift in how value is created and sustained within the European Union. The "Great Rationalisation" and Industrial Maturity As the sector moves away from the "speculative fragmentation" of the early 2020s, the focus has shifted toward EBITDA and industrial logic. High-growth, high-burn companies are seeing their multiples compressed, while profitable platforms command premium valuations. Hubs like Porto and Wroclaw, which combine a lower cost of operation with a highly technical talent base, are uniquely positioned to foster companies that meet these new efficiency requirements. Capitalising on the European Health Data Space (EHDS) The implementation of the EHDS is expected to redefine the competitive "moat" for HealthTech companies. By 2029, the ability to successfully navigate the EHDS framework for secondary data use will distinguish leaders in precision medicine and AI diagnostics. Wroclaw’s investment in genomic data sovereignty and Ghent’s development of AI-specific infrastructure ("The Brain") are strategic moves intended to capture early-mover advantages in this data-centric environment. Master the Data "Plumbing" and Interoperability Investors in 2026 are increasingly targeting the "unsexy" backend infrastructure of healthcare—the data plumbing that enables interoperability and fluidity. This includes sovereign cloud adoption, secure EHR integration, and standardized diagnostic APIs. The development of the AWS European Sovereign Cloud for medication dispensing systems like BD’s Pyxis Pro illustrates the growing importance of data privacy and residency in the EU market. Conclusion: The Binary Future of Compliance The convergence of MDR, IVDR, the AI Act, and the Corporate Sustainability Reporting Directive (CSRD) in 2026 creates a binary outcome for MedTech ventures: those with certificates are investable assets; those without are distressed liabilities. Ghent, Porto, and Wroclaw have recognised this reality by building specialised support structures, from regulatory consulting at UPTEC to clinical test-beds at the ARC Innovation Hub, designed to shepherd startups through the "Regulatory Darwinism" of the current era. By 2029, these three hubs are expected to have moved beyond the "emerging" phase into full industrial maturity. Ghent will likely be a global center for CAR-T and advanced biologic manufacturing; Porto will serve as the Southern European vanguard for AI-driven virtual care; and Wroclaw will have established itself as the Central European authority on genomic data and high-precision MedTech R&D. For founders, investors, and pharmaceutical partners, the trajectory of these hubs represents a clear roadmap for the future of healthcare innovation in Europe. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Doctolib's 40% Secondary Market Devaluation: Primary Drivers of European HealthTech Market Recalibration Structural Devaluation and Strategic Reorientation: A Comprehensive Analysis of Doctolib’s Market Recalibration from 2022 to 2026 The valuation trajectory of Doctolib between the first half of 2022 and the first quarter of 2026 represents a seminal case study in the maturation of the European HealthTech ecosystem. During this period, the company’s implied market value shifted from a primary funding peak of €5.8 Billion to a secondary transaction valuation of €3.6 Billion, marking a 40% decrease that has sparked extensive debate among industry analysts and institutional investors. Source: https://www.bloomberg.com/news/articles/2026-04-02/startup-doctolib-s-valuation-slides-38-in-secondary-share-sale This adjustment occurs despite the company’s sustained operational growth, characterised by an annual recurring revenue (ARR) reaching €422 Million by the end of 2025. The divergence between rising fundamental performance and declining equity valuation is not an isolated phenomenon but is symptomatic of a broader "tech market normalisation" that has recalibrated the premiums once afforded to high-growth, venture-backed enterprises. The primary catalyst for the current €3.6 Billion valuation was a €300 Million secondary share sale facilitated by long-term employees and early angel investors seeking liquidity after more than a decade of company operations]. This transaction, involving prominent new backers such as the Strüngmann family office ATHOS KG, Denmark’s A.P. Moller Holding, and Generation Investment Management (GenIM), highlights a strategic shift from speculative capital to "industrial-grade" institutional support. To understand this 40% devaluation, one must analyse the confluence of macroeconomic multiple compression, the technical mechanics of secondary market discounts, the post-pandemic stabilisation of telemedicine demand, and the pivot toward enterprise-wide profitability in a high-interest-rate environment. The Macroeconomic Paradigm Shift: From Speculative Fervor to Rational Exuberance The valuation of €5.8 Billion established in March 2022 was the product of a unique historical moment characterised by near-zero interest rates and an unprecedented acceleration of digital transformation in healthcare. By 2026, the cost of capital had fundamentally altered the discounted cash flow (DCF) models used by growth equity firms. The tech-heavy Nasdaq index’s 7% decline in early 2026 is merely the most recent indicator of a sustained trend where investors have aggressive discounted future cash flows in favor of present-day profitability. The Collapse of the Growth-at-All-Costs Multiple In late 2021 and early 2022, top-tier SaaS and HealthTech companies were trading at revenue multiples that exceeded 18x to 20x. Doctolib’s €5.8 Billion valuation on an estimated revenue base of €250 Million to €300 Million placed it firmly within this elite, albeit speculative, bracket, with an implied price-to-sales multiple of approximately 19.3x to 23x. By March 2026, the median public SaaS revenue multiple had compressed to 3.4x, reflecting a broader market realisation that the era of hyper-expansion subsidised by cheap venture capital had ended. Period Valuation ARR (Est.) Implied Multiple (Multiple=ARREV​) Q1 2022 €5.8 Billion [User Query] ~€270 Million ~21.5x Q1 2026 €3.6 Billion [User Query] ~€422 Million [User Query] ~8.5x As the table illustrates, while Doctolib’s revenue grew by over 50%, its multiple compressed by more than 60%. This compression is the primary driver of the 40% valuation drop. In a high-interest-rate environment, the value of a dollar earned ten years from now is significantly lower than it was in 2021. For a company like Doctolib, which was not yet profitable at the time of its Series G raise, this shift in the discount rate exerted immediate downward pressure on its "paper" valuation. The Technical Nature of Secondary Transaction Discounts A critical nuance in the €3.6 billion figure is that it stems from a secondary share sale rather than a primary financing round. In the private markets of 2026, secondary transactions are fundamentally different from primary rounds in their pricing mechanisms. Primary rounds involve the issuance of new equity to fund growth, whereas secondary rounds involve existing shareholders selling their stakes to new investors. Secondary shares typically trade at a "liquidity discount" of 10% to 30% relative to the last primary round. This discount compensates the buyer for several risks: Illiquidity: The shares cannot be sold on a public exchange and have no definitive exit timeline. Preference Gap: Secondary shares are often common stock or lack the liquidation preferences and anti-dilution protections granted to primary investors in later rounds. Information Asymmetry: Secondary buyers may have less access to internal company data than lead investors in a primary round. The €3.6 Billion valuation thus represents a "fair market value" for a block of shares being sold for cash today, rather than a theoretical enterprise value for the whole company in a competitive bidding process. For Doctolib’s management, accepting a lower valuation for this "small secondary round" was now doubt a strategic choice to satisfy the liquidity needs of angel investors and long-term employees who had been with the company since its 2013 founding. Post-Pandemic Normalisation and the Telemedicine Plateau Doctolib’s earlier, higher valuation was significantly buoyed by the "COVID-19 effect". During the pandemic, the company became an essential infrastructure provider, particularly in France, where it handled the logistics of national vaccine rollouts. This period saw a massive spike in telemedicine adoption, with virtual consultations jumping from 1% of total medical visits to 17% in a matter of months. The Reversion to Hybrid Care Models By 2026, the "telemedicine-only" hype of 2021 had settled into a more nuanced "hybrid care" reality. Market data from 2022 through 2026 shows that telemedicine usage has stabilised at approximately 4% to 6% of all consultations. While this is a permanent and significant increase from pre-pandemic levels, it fell short of the 20% to 30% penetration rates that some investors had projected during the peak of the crisis. Metric Pre-Pandemic (2019) Pandemic Peak (2020/21) Normalization (2022-26) Telemed % of Visits ~1% 17% 4% - 6% Doctolib Focus Booking Utility Emergency Health Infrastructure Healthcare Operating System This normalisation forced a recalibration of Doctolib’s growth trajectory. The company transitioned from a phase of "forced adoption" to one where it had to prove the long-term efficiency gains of its platform in a post-crisis environment.The market no longer values Doctolib as a pandemic beneficiary but as a standard utility, which naturally commands a more conservative multiple. From "Booking App" to "Healthcare Operating System": Strategic Reorientation To counter multiple compression and declining pandemic tailwinds, Doctolib has undergone a fundamental product transformation. In 2022, the platform was largely viewed as a digital gateway for patient appointments. By 2026, the company is positioning itself as an integrated "Operating System" for healthcare professionals, harmonising administrative, clinical and financial workflows. The Integration of Agentic and Ambient AI Doctolib’s R&D strategy, which saw an investment of €115 Million in 2024 alone, is centred on the integration of artificial intelligence into the clinician’s daily workflow. Doctolib launched an "Ambient AI Scribe," a tool that converts spoken patient-doctor dialogue into structured clinical documentation. This technological shift is designed to address the global shortfall of 11 Million healthcare workers by reducing the administrative documentation time by an estimated 50%. The business implication of this shift is profound. By moving from a "booking fee" model to a "clinical efficiency" model, Doctolib can justify higher subscription tiers. Currently, practitioners pay a baseline of €139 per month, but the full suite of integrated services, including AI scribing, automated reception via Aaron.ai and financial management tools—can cost up to €500 per month. Operational Efficiency and the Path to Profitability In the era of "Rational Exuberance," the most critical metric for a late-stage startup is the "Rule of 40," defined by the formula: $Score = Revenue Growth Rate + EBITDA Margin A score above 40% is considered the gold standard for SaaS health. Doctolib has spent the 2023-2025 period aggressively moving toward this benchmark by narrowing its losses. Year Revenue (ARR) Adjusted EBITDA Net Loss Reduction 2023 €284.1M -€87.1M - 2024 €348.0M -€53.8M 38% 2025 €422.0M [User Query] Breakeven ~100% (Projected) The reduction in losses from €87.1 Million to €53.8 Million in a single year demonstrates a disciplined management team capable of balancing high R&D intensity (33% of revenue) with fiscal responsibility. This transition is a prerequisite for the company’s anticipated IPO in late 2026 or 2027, as public market investors in the current regime are unwilling to subsidise "unprofitable growth". Competitive Landscape and European Market Maturity Doctolib’s 2026 position is also defined by its relative dominance in the European market compared to peers like Poland’s DocPlanner. While DocPlanner has raised significantly less capital ($141 Million compared to Doctolib’s ~$866 Million), it remains a formidable rival in fragmented markets like Italy and Spain. Consolidation and Regional Dynamics The European digital health market has moved from a period of "fragmented speculation" to one of "strategic consolidation". Doctolib has successfully defended its home market of France, where it supports 19 Million patients and 200,000 healthcare professionals, while aggressively expanding into Germany. Germany now accounts for approximately 20% of Doctolib’s total ARR and is the primary driver of new growth, contributing 28% of new revenues in Q1 2025 . However, international expansion is a double-edged sword for valuation. While it increases the addressable market, the "slow and tricky" nature of recruiting doctors in different regulatory environments (as noted by DocPlanner’s CFO) means that customer acquisition costs (CAC) remain high. This slower-than-expected international uptake compared to the lightning-fast growth in France has likely contributed to the more conservative 2026 valuation. Company Total Funding Employees Patient Base Market Strategy Doctolib ~$866M ~3,500 ~80M (EU) Integrated OS DocPlanner ~$141M ~1,500 ~30M (Global) Market Aggregator Comparison with US Peers: Hinge Health and Omada When benchmarked against US peers like Hinge Health, Doctolib’s valuation compression appears part of a global reset. Hinge Health, valued at $6.2 Billion in 2021, filed for an IPO in 2025 with a target valuation of only $2.6 Billion, reflecting a similar 50%+ reduction in enterprise value despite growing revenues. Doctolib’s 40% drop is actually "resilient" compared to some US peers, likely due to its more stable, subscription-based European revenue model, which is less sensitive to the employment cycles that impact US employer-driven health plans. Doctolib's 40% Secondary Market Devaluation: Primary Drivers of European HealthTech Market Recalibration Regulatory Darwinism: The EU AI Act and Compliance Moats A subtle but powerful factor in Doctolib’s 2026 valuation is the "Compliance Moat" created by the European regulatory environment. As of March 2026, the full enforcement of the EU AI Act has created a binary filter for investors. The Valuation Premium for Regulatory Compliance Companies that have achieved Medical Device Regulation (MDR) certification and comply with the "high-risk" AI standards of the EU AI Act now command a 20-30% valuation premium. This is because compliant assets represent a "turnkey" solution for strategic buyers (like Siemens or Roche) who want to enter the digital health market without facing an 18-to-24-month regulatory bottleneck. Analysing the New Investor Pool: ATHOS, GenIM, and A.P. Moller The €300 Million secondary sale brought in a new class of investors whose presence provides deep insight into the company’s future. The shift from traditional Venture Capital (like Accel or Eurazeo) to family offices and industrial holdings (ATHOS KG, A.P. Moller Holding) suggests a transition from "exit-seeking" capital to "value-building" capital. Rationale of New Institutional Backers ATHOS KG: The family office of the Strüngmann brothers, who famously backed BioNTech. Their investment signals a belief in Doctolib’s long-term role as a central pillar of the European medical infrastructure. A.P. Moller Holding: Known for long-term "industrial" investments. Their participation suggests that Doctolib is no longer viewed as a high-risk tech startup but as a foundational utility platform with predictable, subscription-based cash flows. Generation Investment Management (GenIM): Chaired by Al Gore, GenIM focuses on sustainable, long-term growth. Their involvement underscores Doctolib’s "B-Corp" status and its social utility in solving the healthcare worker shortage. These investors are comfortable with a "flat" or "discounted" valuation in 2026 because they are pricing the asset based on its 2030 potential rather than its 2021 hype. Their entry at €3.6 Billion effectively sets a "floor" for the valuation and de-risks the eventual path to an IPO. The IPO Horizon (2026-2027): Valuation Recovery and Listing Dilemmas As the company enters the 2026-2027 IPO window, the focus shifts to whether it can reclaim its €5.8 Billion (or $6.4 Billion) peak. Current analysts suggest an IPO target in the range of $6 billion to $8 Billion, contingent on several factors. Factors for a Successful Public Debut Demonstrated Profitability: The company must prove it can be EBITDA-positive while maintaining a 20%+ growth rate. The "Delaware Flip": There is strategic debate about whether Doctolib should list on a US exchange (NASDAQ) to capture higher valuation multiples or remain on Euronext as a European champion. A US listing might offer 20-30% higher multiples but would require a complex legal restructuring. Market Sentiment: The success of "bellwether" listings, such as Belgium’s Agomab Therapeutics, has indicated that investor appetite for "de-risked European assets" is returning in early 2026. Valuation Benchmarks for 2026 IPOs Metric Digital Health Platform Target Doctolib 2026 Position Gross Margin 60% - 80% ~65% - 70% ARR per FTE $150k - $200k ~$130k (Estimating ~3,500 staff) NRR (Net Retention) >110% High (99% subscription based) Regulatory Status Compliant (AI Act/MDR) High Moat Doctolib’s position as a "category leader in waiting" is strong, but the valuation gap between €3.6 Billion and the €6-8 Billion target must be filled by proof of AI-driven margin expansion. Conclusion: Synthesising the 40% Devaluation The 40% decrease in Doctolib’s valuation from Q1 2022 to Q1 2026 is a multifaceted phenomenon that reflects the maturation of both the company and the broader tech market. It was caused not by a decline in business utility, as evidenced by the growth to €422 Million ARR, but by a dramatic shift in how the market prices that utility.. The primary drivers of this recalibration include: The Correction of "Pandemic Premium": The realisation that telemedicine is a hybrid supplement rather than a wholesale replacement for in-person care. Interest Rate Reality: The end of the "Growth at All Costs" era, which forced a transition from 20x multiples to 8x multiples. Secondary Market Mechanics: The technical requirement of providing liquidity to early backers at a market-clearing discount. Strategic Reinvestment: The decision to prioritise a €115 Million R&D budget (33% of revenue) to build a defensible AI-driven "Operating System" rather than chasing immediate short-term profitability during a market downturn. Far from being a sign of distress, the €3.6 Billion valuation and the accompanying €300 Million secondary sale represent a "cleaning" of the cap table. By replacing early, risk-averse angels with industrial giants like A.P. Moller and ATHOS, Doctolib has secured the patient capital necessary to navigate the final steps toward an IPO. The company is no longer a "startup" in the speculative sense; it is a mature European health infrastructure provider entering a new era of "Industrial Maturity". The success of its AI initiatives and its expansion in Germany will ultimately determine if the next phase of its financial journey, the public markets, will see a return to the premiums of its pandemic-era peak. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Evaluation of Large Language Models for Medical Applications: The integration of Large Language Models (LLMs) into the clinical environment represents one of the most significant shifts in healthcare technology since the advent of the Electronic Health Record (EHR). While early-stage models demonstrated an extraordinary capacity for passing standardized medical licensing examinations, a profound "benchmarking gap" has emerged between academic performance and clinical readiness. Traditional evaluations, often centered on multiple-choice formats such as the United States Medical Licensing Examination (USMLE), fail to capture the procedural complexity, longitudinal context, and high-stakes decision-making inherent in real-world patient care. To address these deficiencies, the Holistic Evaluation of Large Language Models for Medical Applications (MedHELM) framework was developed as a specialised, extensible benchmarking system designed to measure LLM performance across 121 distinct medical tasks. This framework, born from a collaboration between the Stanford Center for Research on Foundation Models (CRFM), Stanford Healthcare, and Microsoft Healthcare, serves as a rigorous audit mechanism for assessing the clinical utility, safety, and reliability of generative AI in medicine. Theoretical Foundations of the MedHELM Taxonomy The primary contribution of MedHELM is a clinician-validated taxonomy that organizes medical AI applications into functional domains mirroring the daily activities of healthcare providers. The development of this taxonomy involved 29 clinicians representing 14 different medical specialties, ensuring that the tasks evaluated reflect the ground truth of clinical workflows rather than synthetic or abstract scenarios. The taxonomy is structured hierarchically into five primary categories, which are further divided into 22 subcategories and 121 specific tasks. Clinical Decision Support and Diagnostic Reasoning Clinical Decision Support (CDS) is the most critical domain in the MedHELM framework, as it directly impacts patient outcomes. The taxonomy identifies four subcategories within CDS: supporting diagnostic decisions, planning treatments, predicting patient risks and outcomes, and providing clinical knowledge support. Unlike static examinations that test for isolated facts, MedHELM’s CDS evaluation utilizes multi-turn case vignettes where the patient’s condition may evolve over time. This requires models to demonstrate "differential diagnosis generation," where multiple potential diagnoses are ranked by likelihood, reflecting the ambiguity often encountered in primary care or emergency medicine. The transition to evaluating "longitudinal care context" rather than one-off prompts is a foundational shift. Clinical practice often involves navigating missing lab values, inconsistent patient histories, and the need to reconcile current findings with prior documented history. MedHELM probes these areas by assessing how a model reacts when information is borderline or absent, penalising "over-confident wrong answers" through calibration metrics. Clinical Note Generation and Documentation Workflows The administrative burden of medical documentation is a leading cause of clinician burnout, making "Clinical Note Generation" a high-value application area for LLMs. The MedHELM taxonomy breaks this domain into documenting patient visits, recording procedures, documenting diagnostic reports, and creating care plans. The evaluation focuses on "documentation integrity," specifically checking for "prompt drift" or the inappropriate propagation of outdated information through the EHR. Performance in note generation is not merely about linguistic fluency but about "factuality versus the source of truth," such as laboratory results, imaging reports, and patient charts. Models are tested on their ability to generate structured summaries from unstructured inputs, ensuring completeness in critical sections like medications, allergies, and follow-up plans. Patient Communication and Education Effective communication is essential for health literacy and patient adherence. MedHELM evaluates models across five subcategories: providing educational resources, delivering personalized care instructions, supporting patient-provider messaging, enhancing accessibility, and facilitating patient engagement. A significant focus in this category is "plain-language explanation," where complex medical terminology must be translated for lay audiences without losing clinical accuracy. Safety-critical elements of patient communication include "adherence to scope limits," where models must avoid acting as a replacement for human clinicians and explicitly instruct patients to seek urgent care when "red-flag" symptoms, such as unilateral weakness or severe chest pain, are present. The framework specifically looks for the absence of off-label treatment suggestions and the consistent use of clear "see your doctor" disclaimers. Medical Research Assistance and Evidence Grounding Medical research tasks in MedHELM include literature research, clinical research data analysis, recording research processes, ensuring research quality, and managing enrollment. A key benchmark within this domain is the evaluation of models on "Real-World Evidence" (RWE) studies. Unlike general summarisation, RWE summarisation requires the model to extract and present statistically significant outcomes, including numeric values such as odds ratios (ORs), confidence intervals (CIs), and p-values. The "RWESummary" framework within MedHELM defines specific metrics for success in research assistance: "Direction of Effect" (correctly assigning positive, negative, or no difference outcomes), "Numeric Accuracy," and "Completeness" (inclusion of all outcomes where $p \le 0.05$). This ensures that AI systems assisting researchers are grounded in the actual evidence of the study rather than generating plausible-sounding hallucinations. Administration and Workflow Optimisation The "Administration and Workflow" category remains the most challenging for current LLMs, with lower performance scores compared to clinical categories. The taxonomy includes tasks like scheduling resources, overseeing financial activities, organising workflow processes, and care coordination. These tasks often involve complex "Text-to-SQL" generation, where a model must query an EHR database to extract specific patient populations or billing codes. The following table details the functional distribution of the MedHELM taxonomy, providing a comprehensive overview of the categories and subcategories validated by the clinical review panel. Primary Category Subcategory Count Total Task Count Representative Tasks Clinical Decision Support 4 24 Differential diagnosis, treatment planning, risk prediction, knowledge retrieval Clinical Note Generation 4 22 Visit notes, procedure reports, diagnostic summaries, care plan documentation Patient Communication 5 28 Education materials, instructions, portal messaging, health literacy support Medical Research 5 26 Literature review, trial data analysis, enrollment management, quality compliance Administration & Workflow 4 21 Resource scheduling, billing/financial tasks, referral triage, care coordination Benchmarking Methodology and Evaluative Metrics MedHELM utilises a holistic approach to measurement, moving beyond simple accuracy to include robustness, calibration, fairness, and toxicity. This is achieved through a combination of 35 distinct benchmarks, including 14 private datasets, 7 gated-access datasets (e.g., PhysioNet), and 14 public benchmarks. The LLM-Jury and "LLM-as-a-Judge" Mechanism One of the most innovative aspects of MedHELM is its use of an "LLM-jury" to evaluate open-ended text generation.Because medical responses are context-dependent and often lack a single "gold standard" answer, the framework uses an ensemble of high-performing reasoning models (e.g., GPT-4o, Claude 3.7 Sonnet, Llama 3.3 70B) to rate responses against tailored rubrics. These jurors evaluate dimensions such as accuracy, completeness, and clarity on a Likert-5 scale. The agreement between the LLM-jury and human clinicians is measured using the Intraclass Correlation Coefficient (ICC). The MedHELM LLM-jury achieved an ICC of 0.47, which exceeded the average agreement between two human clinicians (ICC = 0.43). This indicates that the AI panel provides a more consistent and reproducible evaluation than traditional human peer review, although it is not without its own set of biases, such as "self-preference" for models from the same developer. Recursive Rubric Generation: One-Question-One-World (Qworld) To address the limitations of static rubrics, the MedHELM framework incorporates the "One-Question-One-World" (Qworld) method. Qworld generates question-specific evaluation criteria using a recursive expansion tree. For any given clinical question, the system decomposes it into various scenarios and perspectives, creating fine-grained binary criteria that specify what a high-quality answer must address for that specific context. This approach prevents the oversimplification that occurs when a single rubric is applied to a diverse dataset, allowing for more nuanced assessments of complex clinical reasoning. Standardised Performance Metrics MedHELM reports a variety of metrics tailored to the nature of the clinical task: Mean Win Rate: The percentage of head-to-head comparisons where a model’s response is preferred by the jurors. Jury Score: The average normalised score from the three frontier LLM jurors. MedCalc Accuracy: A specialised metric for medical calculations that uses either exact match or thresholded matching depending on the nature of the question. EHRSQLExeAcc: The execution accuracy of generated code against a target EHR database. Harm-Weighted Error: A risk-aware metric that penalises dangerous or contraindicated recommendations more heavily than minor guideline drifts. Comparative Analysis of Model Performance The MedHELM leaderboard provides a comprehensive ranking of leading LLMs based on their mean win rate across the taxonomy’s tasks. The evaluation reveals significant performance variation, particularly between "reasoning" models and general "instruction-tuned" models. Leading Models and Performance Rankings As of early 2026, the performance standings are dominated by frontier models from OpenAI, Anthropic, Google, and DeepSeek. GPT-5 currently holds the top position with a mean win rate of 0.703, followed closely by the reasoning optimised o4-mini and GPT-5 mini. Model Release/Access Date Mean Win Rate Primary Strength Domain GPT-5 2025-08-07 0.703 Factual knowledge, quantitative reasoning o4-mini 2025-04-16 0.697 Clinical logic, efficient reasoning GPT-5 mini 2025-08-07 0.690 Task-specific accuracy, cost efficiency o3-mini 2025-01-31 0.572 Structured data manipulation, research DeepSeek R1 2025-01-31 0.565 Multi-step reasoning, medical calculation Claude 3.5 Sonnet 2024-10-22 0.542 Patient communication, empathy, safety Claude 3.7 Sonnet 2025-02-19 0.529 Balanced reasoning and cost-effectiveness Gemini 2.5 Pro 2025-05-06 0.519 RWE summarization, numeric fidelity GPT-4o 2024-05-13 0.491 General medical QA, diagnostic support Gemini 2.0 Flash 2024-12-06 0.360 High-speed summarisation, low-risk admin Category-Specific Strengths and Weaknesses Models exhibit distinct performance patterns across the five MedHELM categories. Reasoning models like DeepSeek R1 and o3-mini demonstrate superior performance in Clinical Decision Support and Medical Research Assistance, often achieving win rates of 66%. Conversely, models like Claude 3.5 Sonnet are highly competitive in Clinical Note Generation and Patient Communication, often providing comparable quality at a significantly lower computational cost. In terms of normalised accuracy scores (0–1 scale): Clinical Note Generation: 0.74 – 0.85 (Strong) Patient Communication & Education: 0.76 – 0.89 (Strong) Medical Research Assistance: 0.65 – 0.75 (Moderate) Clinical Decision Support: 0.61 – 0.76 (Moderate) Administration & Workflow: 0.53 – 0.63 (Lower) These results suggest that while LLMs are becoming reliable tools for summarisation and communication, they still struggle with the complex logistics and structured data manipulation required for hospital administration. Specialised Benchmarks: Probing Failure Modes and Risks Beyond general performance, MedHELM includes specialised scenarios designed to probe specific safety risks and technical capabilities. These benchmarks often reveal a "Benchmarking Gap"—a profound discrepancy between high performance on multiple-choice exams and low reliability in dynamic clinical scenarios. MedCalc-Bench and Quantitative Reasoning Medical calculations are notoriously difficult for LLMs due to a reliance on next-token prediction rather than deterministic arithmetic. MedCalc-Bench evaluates models on 55 calculators from the MDCalc database using patient vignettes sourced from case reports. The benchmark tests "faithfulness" by examining whether a model’s reasoning trace aligns with the final calculation. Research indicates that even "reasoning" models like DeepSeek R1 and o3-mini have significant room for improvement in this domain, with current leaders achieving scores around 0.35. However, the integration of agentic tools, such as code interpreters—can lead to a 13-fold reduction in errors for certain GPT-based models. EHRSQL and Structured Data Extraction The ability to translate natural language into SQL queries is vital for hospital analytics. The EHRSQL benchmark assesses how well a model can extract patient data while maintaining the integrity of the database schema. Failures in this scenario are particularly risky, as they can lead to incorrect medication list extraction or faulty clinical risk estimates. Interestingly, some newer models have shown "regressions" in this area; for instance, GPT-5 saw a 0.14 drop in EHRSQL performance compared to GPT-4o, highlighting the difficulty of maintaining strict "schema-grounded" generation in models optimised for conversational fluidness. RaceBias and Fairness Evaluations The potential for algorithmic bias in healthcare is a major regulatory concern. The MedHELM "RaceBias" scenario probes whether models provide different treatment recommendations based solely on a patient’s race. Results have been concerning: one study found that cognitive-bias priming altered clinical recommendations in 81% of fairness tests for certain models. On the current leaderboard, DeepSeek R1 leads in fairness robustness with a score of 0.92, while other top-tier models have shown substantial deficits in this area, necessitating priority remediation before production deployment. MedHallu: Hallucination Resistance Hallucinations—the confident generation of clinically incorrect information—are evaluated in the "MedHallu" scenario.This is particularly relevant for "rare diseases" or "drug-drug interactions" where model training data may be sparse.Claude 3.5 Sonnet currently holds the highest score (0.93) in MedHallu, indicating a higher degree of caution and adherence to grounded medical facts compared to more "creative" generative models. Economic and Computational Considerations The cost-performance analysis is a key component of MedHELM, enabling healthcare organizations to make "evidence-based selection" of models based on their budget and latency requirements. Total Cost of Evaluation Running the comprehensive MedHELM benchmark suite is computationally expensive. Evaluation costs include both the "benchmark runs" (generating model outputs) and the "jury evaluation" (the LLM-jury assessing those outputs). For a full evaluation of 35 benchmarks, costs represent upper-bound estimates based on maximum output token usage. The following table compares the computational costs for several frontier models evaluated on the MedHELM suite. Model Benchmark Cost Jury Cost Total Evaluation Cost Token Count (Benchmark) DeepSeek R1 $848.21 $957.96 $1,806.17 334,133,126 o3-mini $762.50 $959.54 $1,722.04 337,967,189 Claude 3.5 Sonnet $778.67 $792.21 $1,570.88 245,958,343 Claude 3.7 Sonnet $768.26 $768.38 $1,536.64 242,510,517 GPT-4o $647.28 $765.91 $1,413.19 248,731,118 Gemini 1.5 Pro $359.33 $771.73 $1,131.06 277,273,571 Gemini 2.0 Flash $43.04 $771.73 $814.77 276,777,154 Latency and Efficiency In fast-paced clinical settings, such as emergency departments or intensive care units, latency is a critical factor. The mean per-instance latency for frontier models varies significantly. For example, GPT-5 has a mean latency of 15.05 seconds per instance, which is roughly 1.11 times slower than previous leaders. Models optimised for speed, such as Gemini 2.0 Flash, can achieve latency as low as 0.34 seconds for certain tasks, making them more suitable for real-time administrative support. Technical Implementation and Extension MedHELM is built upon the foundational HELM architecture and is designed to be "extensible," allowing healthcare institutions to incorporate their own private datasets and custom clinical tasks. System Requirements and Installation To install and run MedHELM, the framework requires: Python 3.10: It is only compatible with this version despite recommendations for newer versions during the Google Cloud CLI install. Conda: Used for virtual environment isolation. Google Cloud CLI: Necessary for downloading results and leaderboard metadata. GPU Access: Required for running models locally; exact requirements vary by model size and context length. Creating Custom Benchmarks Users can extend MedHELM by following a five-step process: Prompt Template (.txt): Define instructions using placeholders like {patient_id} and {note} that match CSV columns. Dataset (.csv): Prepare clinical data where each row represents a benchmark instance, including correct_answer and incorrect_answers columns Benchmark Configuration (.yaml): Define the name, description, and metric list (e.g., exact_match, jury_score). Run Configuration (.conf): Specify model names and deployments (e.g., HuggingFace, OpenAI). Execution: Use the helm-run and helm-summarise commands to generate results and interactive leaderboards. Integration with Clinical Infrastructure Deployment in a live hospital environment requires strict adherence to privacy and security protocols. Governance frameworks developed in collaboration with legal and cybersecurity teams ensure "responsible innovation". Access control is typically enforced through the "SMART on FHIR" launch protocol, which delegates authorisation to the EHR system and ensures the principle of "data minimisation", the AI system only retrieves data the user is already authorised to view. No persistent data storage occurs outside the application runtime session, minimising the surface area for potential misuse. Critical Analysis and Current Challenges While MedHELM represents a significant leap forward in medical AI evaluation, it faces several ongoing challenges related to reproducibility, dataset access, and the evolving nature of foundation models. The Reproducibility Gap A major point of contention in the medical AI community is the "reproducibility gap" created by private datasets. While 14 of MedHELM's datasets are based on real patient records to ensure clinical relevance, these datasets cannot be publicly released due to regulatory and privacy constraints. This prevents the broader research community from fully replicating the leaderboard results, although it provides a more accurate reflection of "real-world performance" than synthetic datasets. Data Contamination and Static Benchmarks Data contamination remains a plague for public benchmarks like MMLU or MedQA, as these questions often appear in model training sets. MedHELM’s inclusion of proprietary and gated datasets (like MIMIC-IV or Atropos Health data) is an attempt to mitigate this issue by testing models on "unseen" clinical scenarios. However, even these datasets risk becoming "stale" over time, necessitating the constant addition of new tasks—a process evidenced by the expansion from 98 to 121 tasks during the framework’s validation phase. LLM-Human Alignment A core question in MedHELM’s evaluation is whether an AI judge can truly replace human clinician judgment. While the ICC agreement scores are encouraging, research shows that humans still provide a more "nuanced understanding" of complex patient cases and are better at identifying "semantic distortions" that an LLM might miss. The framework acknowledges this by positioning the LLM-jury as a "complementary evaluator" that accelerates early-stage inspections in safety-critical environments rather than a final arbiter of clinical truth. Future Directions: Multimodal and Agentic Medical AI The MedHELM framework is architecturally agnostic, meaning it can be extended to multimodal models that integrate text with medical imaging and laboratory data. Multimodal Evaluations for Neuro Imaging Early multimodal extensions of MedHELM have begun evaluating vision-enabled LLMs on neuroimaging datasets (MRI and CT). Models are required to generate multiple outputs simultaneously, such as diagnosis, subtype, and anatomical plane. Findings indicate that while tumuor classification is highly reliable, rare abnormalities and stroke symptoms remain difficult for current vision-language models to solve accurately. The Rise of Medical Agents The focus of evaluation is shifting from static knowledge retrieval to "complex, multi-turn clinical reasoning and agentic interactions". Future iterations of MedHELM are expected to evaluate "teams of agents"—multiple LLM instances with specialised subtasks that jointly solve data analysis problems, much like a human research team. This includes systems like "HeartAgent," which integrates customised tools to perform complex reasoning while providing "verifiable supporting references". Clinical Governance and Policy Implications For hospital leadership and regulators, MedHELM offers a map of "failure modes" that is critical for risk mitigation. Model Selection by Risk Class MedHELM’s category-level scores suggest a risk-based approach to model selection: Low Risk: Drafting patient education leaflets or resource scheduling (General-purpose or "Flash" models). Moderate Risk: Documentation support and visit summaries (Fine-tuned medical models with high factuality scores). High Risk: Diagnostic suggestions, triage, and medication changes (Frontier reasoning models with exhaustive safety red-teaming). Regulatory Alignment In jurisdictions like the Russian Federation, LLM-based medical methods are classified as "Class III high-risk technologies" due to the potential for hallucinations. MedHELM provides the "standardized, reproducible comparisons" and "objective quantification" required by regulators to validate these systems before they reach patient care. The use of frameworks like MINIMAR (Minimum Information for Medical AI Reporting) alongside MedHELM helps ensure that the data sources and evaluation methods are transparently documented. Synthesis and Conclusion The MedHELM framework addresses a foundational need in the era of generative medicine: a way to evaluate LLMs that is as complex and diverse as medical practice itself. By moving beyond standardised exams and anchoring assessment in 121 clinician-validated tasks, MedHELM exposes the "Benchmarking Gap" and highlights the critical importance of reasoning, fairness, and documentation integrity. The empirical results from 2025 and 2026 demonstrate that while frontier models are increasingly capable of supporting clinical documentation and patient education, the path to autonomous diagnostic reasoning is fraught with challenges related to mathematical precision, structured data extraction, and deep-seated bias. For healthcare organisations, MedHELM serves not just as a leaderboard, but as a "foundational, scalable, and living platform" that enables the evidence-based selection of AI systems, ensuring that technology serves to augment clinician capabilities without compromising patient safety. As the framework extends into multimodal and agentic domains, it will remain an essential tool for navigating the risks and realising the immense potential of large language models in healthcare. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

App, Platform, Data, AI: The Four Pillars of Modern Healthcare Technology Infrastructure The evolution of healthcare technology has reached a critical juncture where the traditional, fragmented approach to digital health is being superseded by an integrated, four-pillar architectural framework. This modern infrastructure is characterised by an interlocking relationship between the user-facing Application, the service-orchestrating Platform, the governed Data layer and the value-driving Artificial Intelligence (AI) models that sit atop the stack. For enterprises seeking to build scalable, sustainable and defendable businesses, this configuration represents the fundamental blueprint for success in a landscape increasingly defined by value-based care, precision medicine, and the demand for clinician-centric design. The Application Pillar: Interface Design and Human-Centred Clinical Engagement The application layer serves as the primary interface through which the broader technological ecosystem interacts with its human constituents, specifically clinicians and patients. In the context of a sustainable healthcare technology business, the application is no longer a standalone tool but a sophisticated conduit for workflow orchestration and behavioral engagement. For clinicians, the application must resolve the persistent friction between administrative documentation and direct patient care, while for patients, it must facilitate a transition from passive recipients of care to active participants in health management. Clinician-Facing Applications and the Architecture of Usability The modern clinician lives within the Electronic Health Record (EHR), and any application that forces a departure from this primary environment faces significant adoption barriers. Consequently, the architecture of successful clinician-facing apps is increasingly "embedded" or "context-aware". By utilising standards such as SMART on FHIR, these applications appear as integrated components of the clinical workspace, pulling relevant data automatically and eliminating the need for redundant logins or manual data re-entry. The concept of "intuitive design" has shifted from a mere preference to a strategic necessity. The next generation of healthcare providers expects consumer-grade experiences, and tools that require extensive onboarding or manuals are considered failures in the modern architectural paradigm. One of the most critical metrics for these applications is the "two-click rule," which suggests that any AI-related task or critical data retrieval should require no more than two clicks to minimize cognitive load and maximise compliance. Feature Category Technical Implementation Clinical Impact Smart Defaults Automated pre-population of fields based on EHR data Reduction in documentation time and clerical errors Contextual Nudges Surfacing relevant evidence-based insights at the point of care Improved adherence to clinical guidelines and best practices Tiered Alerting Priority-based classification of clinical notifications Mitigation of alert fatigue and prioritization of critical events Secure Communication End-to-end encrypted role-based messaging channels Enhanced care team coordination and data privacy Patient Engagement and the Shift to Longitudinal Self-Management Patient-facing applications in a sustainable infrastructure are designed to foster long-term engagement rather than episodic interaction. This is achieved through hyper-personalisation, where the application uses clinical data, social determinants of health (SDOH) and behavioural patterns to tailor interventions. For instance, a patient with a chronic condition like diabetes may receive reminders, educational modules and health trackers that are specifically calibrated to their literacy level and cultural context. Engagement is further driven by "Shared Decision-Making" (SDM) modules, where applications provide decision aids, such as visual charts or interactive videos, to help patients understand their treatment options. This creates a sense of ownership over the care plan, which significantly improves treatment adherence and outcomes. The Platform Pillar: Orchestration and the Modularisation of Healthcare Services The platform layer is the "operating system" of the healthcare technology stack, acting as the foundation that connects diverse tools, data flows and user types into a cohesive ecosystem. While an application handles a specific task, the platform orchestrates the underlying services, such as billing, scheduling, and clinical decision support, to ensure they work in harmony. Architectural Patterns for Scalable Infrastructure A scalable HealthTech business must choose an architectural pattern that supports growth without requiring a total system overhaul. Three patterns have emerged as the standard for modern platforms: Microservices, Event-Driven Architecture, and Multi-Tenant SaaS. Microservices : This pattern breaks down a complex platform into small, independent services that perform specific tasks. This allows for "independent scalability," where a high volume of traffic in the scheduling service does not degrade the performance of the billing or clinical records services. Event-Driven Architecture : This model is essential for real-time responsiveness, particularly in remote patient monitoring (RPM). It operates through "events", such as a sensor flagging an irregular heartbeat, which then trigger a cascade of reactions, including pings to the care team and automated logging in the patient's record. Multi-Tenant SaaS : For B2B platforms selling to clinics or hospitals, a multi-tenant architecture is the most efficient model. It allows a single instance of the software to serve multiple organizations (tenants) while ensuring "rock-solid" data isolation and security. The Evolution from Un-bundling to Re-bundling The healthcare platform market is currently experiencing a shift from "un-bundling", where point solutions were built for every individual task—to "re-bundling," where integrated platforms act as hubs for multiple services. These platforms create a "flywheel effect" by becoming more valuable with every new connection and service they orchestrate. They serve as ecosystems that coordinate developers, device makers, and clinical providers, enabling a seamless flow of value across the entire healthcare continuum. Aspect Individual Application End-to-End Platform Core Purpose Handles one specific task (e.g., booking) Acts as a base for multiple workflows and teams Flexibility Rigid structure with limited room for change Modular setup allowing for new feature additions Data Movement Siloed data within its own logic Standards-based connection (FHIR/OpenEHR) Scalability Profile Limited to the specific use case Independently scalable services The Data Pillar: Governance, Integrity, and the Interoperability Mandate Data is the lifeblood of modern healthcare technology, but its value is often locked away in silos or compromised by poor quality and inconsistent governance. A sustainable technology infrastructure treats data as a strategic asset, implementing robust layers for ingestion, transformation and governance. The Challenge of Healthcare Data Silos Despite decades of investment, data silos remain a persistent barrier to innovation. Legacy systems, proprietary formats, and cultural resistance often prevent the free flow of information between payers, providers, and patients. Breaking down these silos requires a combination of technological standards and shared governance frameworks. Recent progress is notable: approximately 70% of U.S. hospitals now engage in four domains of interoperable data exchange, up significantly from previous years. The Medallion Architecture and Data Quality To ensure that data is "AI-ready," many organisations are adopting the "medallion architecture," which categorises data based on its state of refinement: Bronze Layer : Raw, unprocessed data from disparate sources (EHRs, labs, devices). Silver Layer : Data that has been cleaned, deduplicated, and validated through ETL (Extract, Transform, Load) processes. Gold Layer : Aggregated and analysed data that is ready for consumption by AI models or business intelligence tools. Quality in this context is not just about error correction but also about "bias awareness" and "contextual integrity". For example, if a dataset over-samples one demographic, an AI model trained on it will likely reproduce those biases, leading to inequitable care. Interoperability Standards: FHIR and OpenEHR The move toward "liquid data" is facilitated by global standards that allow different systems to speak the same language. HL7 FHIR : Fast Healthcare Interoperability Resources has become the global standard for real-time health data exchange, utilised for its vendor-neutral format and web-based APIs. OpenEHR : More common in Europe, this standard is used for rich, long-term clinical records and semantic interoperability. Interoperability is not just a technical requirement but a strategic one; the most successful platforms are those that move from simply "storing" data to "orchestrating" it in real time across a global ecosystem. The AI Pillar: Driving Clinical and Operational Value through Intelligence AI represents the "intelligence layer" that sits atop the application, platform, and data pillars to drive tangible value. In a modern healthcare technology business, AI is moving from a "passive observer" to an "active operator," capable of identifying risks, automating workflows, and personalising treatment plans at scale. Clinical Decision Support and Predictive Analytics AI models are delivering a significant competitive advantage by streamlining research and providing superior accuracy in diagnostics. By analysing millions of records, AI can identify "care gaps", such as a patient missing a critical screening or being eligible for a clinical trial and flag them directly within the clinical workflow. For instance, AI-driven sepsis detection systems, when integrated smoothly into the EHR, have demonstrated the ability to reduce treatment errors by providing actionable, real-time alerts to care teams. The Role of Large Language Models (LLMs) and Generative AI The integration of LLMs into healthcare is transforming how clinicians interact with information. Stanford’s "ChatEHR" platform illustrates a modern approach, where a "self-hosted gateway" securely connects cutting-edge AI capabilities to the EHR, translating technical FHIR data into clinician friendly structures like treatment plans and episodes of care. To build trust in these clinical GenAI solutions, four pillars of trust are essential: Rigorous Clinical Review : Expert oversight of AI-generated answers to ensure reliability. Real-World Application : Testing in actual clinical settings to evaluate contextually appropriate responses. Curated, Evidence-Based Sources : Utilising trusted medical literature rather than ungoverned open-source data. Continuous Model Improvements : Implementing feedback loops from early adopters to fine-tune algorithms. Evaluating Medical AI: The MedHELM Framework As AI becomes central to care delivery, robust evaluation frameworks are required to ensure safety and efficacy. The MedHELM (Holistic Evaluation of Large Language Models for Medical Applications) framework is a specialised benchmarking system that evaluates LLMs across 121 medical tasks grouped into categories such as Clinical Decision Support, Administration and Patient Communication. This framework ensures that AI performance is measured against real-world healthcare needs rather than just standardised medical exams. AI Capability Mechanism of Value Outcome Goal Predictive Risk Scoring Combining SDOH and clinical data to build risk profiles Reduced avoidable admissions and better value-based care Workflow Automation Automating administrative tasks like claims and billing Reduced manual workload and accelerated reimbursement Information Retrieval Analyzing large volumes of clinical records for rapid insights Enhanced clinician efficiency and diagnostic speed Personalization Engines Adaptive interfaces and tailored care plans Improved patient engagement and adherence Economic Moats and the "Defendability" of HealthTech Businesses A scalable and sustainable healthcare technology business is not only built on its four architectural pillars but also on its ability to create competitive "moats" that protect it from incumbents and emerging rivals. These moats are often generated by the interaction between the pillars themselves. The Data Flywheel and Defensibility The "data flywheel" is a powerful moat where a company's data assets continuously improve its product, attracting more users and generating even more data. Tempus AI provides a clear example of this mechanism: Generate : Their genomics lab sequences oncology samples, creating new molecular data. Ingest : This data is added to their proprietary database of 45 Million patient records. Insight : The increasing volume of data makes their AI models smarter, providing better clinical insights. Scale : Better insights lead to more physicians ordering tests, thus completing the cycle. Switching Costs and Network Effects High switching costs and network effects are standard moats for enterprise healthcare software. Switching Costs : Once a platform like Epic is deeply integrated into a hospital’s clinical and financial workflows, the cost and disruption of switching to a competitor become nearly insurmountable. Network Effects : Platforms become more valuable as more participants join. A telehealth platform with more doctors is more attractive to patients, which in turn attracts more doctors. Vertical AI and Domain Specific Data Moats In the current market, "Vertical AI" companies (those focused on specific industries like oncology, legal, or life sciences) are outperforming horizontal players. Veeva Systems, for example, has built a "Sweet Spot" position by layering AI across a deeply integrated stack of clinical trial management and CRM tools, backed by a domain-specific data moat that horizontal players like Salesforce cannot easily replicate. App, Platform, Data, AI: The Four Pillars of Modern Healthcare Technology Infrastructure Global Implementation: Navigating the US and UK HealthTech Landscapes The path to building a sustainable HealthTech business varies significantly depending on the regulatory and payment structures of the target market. The UK's NHS: A Unified Dataset with Bureaucratic Barriers The UK’s National Health Service (NHS) represents a unique "asset for AI", a theoretically unified dataset for a population of 60 million people. However, the UK market is characterised by several implementation hurdles: Procurement Complexity : The NHS procurement system is often described as overly complex and bureaucratic, with requirements that can deter smaller startups from bidding on contracts. Regulatory Uncertainty : Since Brexit, regulatory uncertainty and the delay in approving new medical devices have shifted some investment toward the US market. Data Rights : In the UK, patients have strong rights over their data, and suppliers generally do not own the information, which differs from the more permissive US model. The US Market: Fragmentation and Commercial Flexibility The US healthcare system is highly fragmented across thousands of payers and providers, creating a different set of challenges and opportunities. Flexible Data Environment : The US offers a more permissive environment for selling and distributing de-identified data (subject to consent), which fuels the growth of "TechBio" companies like Tempus and Flatiron Health. Complex Billing Infrastructure : The sheer volume of payers in the US has fostered a robust software industry dedicated to intricate billing, payment reconciliation, and fraud detection. Market Factor United Kingdom (NHS) United States (Multiple Payers) Data Governance GDPR / MHRA Guidelines HIPAA / Cures Act Market Structure Centralized procurement, finite size Fragmented silos, high flexibility Data Ownership Patient-centric, supplier doesn't own Permissive; high secondary use potential Innovation Drivers AI, genomics, and population health RCM, billing, and clinical efficiency Barriers to Sustainable Healthcare Technology Transformation Despite the clear blueprint provided by the four-pillar infrastructure, several barriers prevent organisations from achieving full sustainability and scalability. Technical and Operational Challenges Many enterprises struggle with the transition from legacy monolithic systems to modern micro-capabilities. This "technical debt" can lead to inconsistent security policies and integration failures. Furthermore, the lack of "explainability" in deep learning models remains a major barrier to clinical adoption; if a clinician cannot trace the reasoning behind an AI prediction, they are unlikely to trust its output. Cultural and Workforce Barriers The success of any technology is ultimately dependent on the people who use it. Resistance to change, "blame cultures" in high-pressure environments, and insufficient funding for change management are significant barriers within the NHS and other large systems. Additionally, the "alert fatigue" phenomenon highlights the need for technology to adapt to clinicians rather than forcing clinicians to adapt to the technology. Future Outlook: The Rise of Agentic AI and Outcome-Based Models As the healthcare technology industry moves toward 2026 and beyond, several trends are poised to redefine the four-pillar architecture. From Copilots to Autonomous AI Agents While the current wave of AI focuses on "Copilots" that assist users, the next generation will be "Agentic AI", systems that autonomously execute multi-step workflows. For example, a CRM agent for healthcare might not just draft an email but research a patient's eligibility for a trial, contact the patient, and update the clinical record without human intervention.This shift will likely move SaaS pricing from "per-seat" to "outcome-based" or "usage-based" models. The Integration of Real-Time "T+0" Infrastructure The "modern data stack" is evolving to support real-time data streaming and inference, moving away from batch processing. This is particularly critical in Pharmacy Benefit Management (PBM) and Claims Adjudication, where architectures must ingest millions of clinical data points to automate decisions with near-zero latency. The Sustainability of the Healthcare Business Model The ultimate goal of the four-pillar infrastructure is to build a sustainable system that optimizes costs while improving quality of care and workforce well-being. By utilising interoperable platforms, AI-driven proactive care, and secure data layers, enterprises can transition from reactive treatment to high-performing, value-based care models. Conclusion: The Path Forward for HealthTech Architects The construction of a scalable, sustainable and defendable healthcare technology business requires a holistic commitment to all four interlocking pillars: App, Platform, Data, and AI. Success is no longer defined by the deployment of a single "killer app" but by the durability and fluidity of the entire ecosystem. As technology leaders transition to decentralised, AI-ready architectures, they must prioritise: Clinical Trust : Building systems that are transparent, evidence-based, and embedded in clinician workflows. Architectural Agility : Adopting domain-driven designs and micro services to allow for global flexibility and rapid innovation. Data Sovereignty : Implementing robust governance and standards-based interoperability to turn raw information into strategic intelligence. Economic Defensibility : Leveraging data flywheels and network effects to create long-term value and competitive moats. The integration of these foundations creates the conditions where innovation moves beyond pilots to scalable implementation, ultimately delivering faster, safer, and more affordable outcomes for patients globally. The legacy of the modern HealthTech architect will not be found in specific lines of code, but in the resilience and impact of the digital ecosystems they build to support the future of human health. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors invited to Judge and Mentor the QSTP x Merck FemTech Accelerator 2026 Nelson Advisors invited to Mentor and Judge the QSTP x Merck FemTech Accelerator 2026 https://nelsonadvisors.co.uk/blog/nelson-advisors-invited-to-mentor-and-judge-the--qstp-x-merck-femtech-accelerator-2026 QSTP x Merck FemTech Accelerator 2026 Qatar Science & Technology Park (QSTP), a member of Qatar Foundation, in partnership with Merck, a leading science and technology company, announced the launch of the QSTP x Merck FemTech Accelerator, a dedicated accelerator designed to support deep tech and impact driven FemTech startups addressing critical unmet needs in women’s health and transforming health outcomes for women across the MENA region. The program will identify and support up to 30 leading FemTech startups developing breakthrough solutions across key women’s health domains, focusing on innovations powered by artificial intelligence, robotics, and materials science. Selected companies will receive access to advanced scaling support, market entry pathways, and clinically aligned pilot opportunities to support commercial expansion into Qatar, with pathways to scale across the wider region. Beyond supporting individual startups, the initiative is designed to generate and track measurable impact at scale, aligned with Qatar Foundation’s mission to improve women’s health outcomes across the region. Through a multi-country approach, the QSTP x Merck FemTech Accelerator will enable deep-tech startups to be piloted, validated, and adopted across multiple markets, addressing women’s health challenges at both regional and global levels. Leveraging QSTP’s innovation ecosystem and Merck’s global scientific and healthcare expertise, selected startups will benefit from curated mentorship, exposure to regional healthcare stakeholders, and opportunities to explore collaboration within Qatar’s health and research landscape. The accelerator will also facilitate engagement with relevant national institutions and ecosystem partners. Aligned with Qatar Foundation’s innovation and healthcare priorities, the accelerator aims to position the country as a regional and global hub for women’s health innovation, while addressing the urgent need for greater investment, research, and commercializ]ation in FemTech, one of the fastest-growing and most impactful sectors in global health technology. Source:  https://qstp.qa/programs/femtech/ Source:  https://qstp.qa/qstp-partners-with-merck-to-launch-femtech-accelerator-advancing-womens-health-innovation/ Nelson Advisors invited to Judge and Mentor the QSTP x Merck FemTech Accelerator 2026 Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

This Week in European MedTech and HealthTech: 2nd April 2026 The final week of March and the beginning of April 2026 have been characterised by a shift toward industrial rigor and regulatory convergence. As the "Great Rationalisation" of European HealthTech continues, the focus has moved from experimental AI to clinical validation and sovereign cloud infrastructure. Here are the major developments in European HealthTech for the week of March 26 – April 2, 2026: 1. Major Product Launches & Sovereign Cloud Adoption BD (Becton, Dickinson and Company): On April 1, 2026, BD launched its Pyxis™ Pro medication dispensing system and Incada™ Connected Care platform in Europe. AWS European Sovereign Cloud: In a significant move for data privacy, BD announced it will host these solutions on the AWS European Sovereign Cloud. This allows EU healthcare providers to meet strict digital sovereignty requirements while maintaining the scale of global cloud infrastructure. 2. Regulatory & Policy Updates AI Act Integration: The European Commission updated its guidance on AI in Healthcare, focusing on aligning the new AI Act with existing MDR/IVDR (Medical Device/In Vitro Diagnostic Regulations). The goal is a "single sectoral route" for certification to prevent high-risk medical AI from needing double approval. MDR "Helsinki Procedure": New proposals are moving forward to codify the "Helsinki procedure," designed to ease bottlenecks for "borderline" products (those that sit between medical devices and other categories like cosmetics or supplements). EU HTA Machinery: The European Health Technology Assessment (HTA) framework is now fully live. Joint clinical assessments are ramping up, raising the bar for the evidence startups need to provide for pan-European market access. 3. Funding & Strategic Initiatives Digital Europe Programme: The EU announced a massive wave of new calls for proposals opening April 20, 2026. Key focus areas include: AI-based image screening in medical centers. Capacity building for the European Health Data Space (EHDS). Digital solutions for regulatory compliance through data. EIT Health: Launched its 2026 Innovation Validation Call, offering up to €850k (50% co-funded) for late-stage digital health projects that are ready for clinical validation and market launch. WHO & Digital Wallets: On March 23, the WHO and partners launched a new initiative to expand the use of digital health wallets, aimed at making personal health records more portable across borders. 4. Biotech & MedTech "Companies to Watch" Isomorphic Labs (UK): The Alphabet spin-off is reportedly preparing for its first human clinical trials using AI-designed small molecules, expected to begin later this year. Vandria (Switzerland): The clinical-stage biotech is gaining traction with its lead asset VNA-318, an oral small molecule targeting mitochondrial function for the treatment of Alzheimer's. CMR Surgical (UK): Its Versius Plus robotic platform has surpassed 40,000 procedures. The company is currently focused on its 2026 U.S. commercialisation push while expanding its digital analytics suite in Europe. To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk   >>>>    The week of March 30 – April 2, 2026, has seen European MedTech pivot toward digital integration, regulatory simplification, and green manufacturing. While the "Great Rationalisation" of post-pandemic funding continues, the focus has shifted to the mandatory adoption of central databases and the refinement of the MDR/IVDR frameworks. Here are the major developments in European MedTech this week: 1. Regulatory "Smarter Certification" & EUDAMED Deadlines European Commission Simplification: On March 31, the Commission advanced a draft regulation to simplify MDR/IVDR requirements. The most notable change is the removal of the rigid five-year certificate validity cap, moving instead toward a continuous, risk-based surveillance model. This is intended to reduce the administrative "bottleneck" that has plagued notified bodies. EUDAMED Countdown: The Commission confirmed that four key modules of the European Database on Medical Devices (EUDAMED) will become mandatory on May 28, 2026. This week, industry leaders issued a final call for firms to validate their device data, as transparency requirements will significantly increase litigation exposure and market visibility starting this summer. UK International Reliance: The MHRA (UK) launched a consultation (closing April 10, 2026) on the indefinite recognition of CE-marked devices in Great Britain. This marks a critical step in the UK's "International Reliance Framework," designed to streamline approvals for devices already cleared by the EU or US FDA. 2. Major Corporate & Clinical Moves BD (Becton, Dickinson and Company): Successfully launched its Pyxis™ Pro and Incada™ Connected Careplatforms in Europe on April 1. Crucially, BD is among the first major players to host these clinical systems on the AWS European Sovereign Cloud, addressing growing EU demands for data sovereignty and local processing. Mölnlycke Health Care: On March 31, the Swedish MedTech giant issued a "Call to Action" regarding the European chronic wound crisis, coinciding with their 2025 Annual Report. The report highlights their "ProcedurePak" trays hitting the 100 million unit milestone, signaling a heavy shift toward sustainable, pre-assembled surgical kits. Johnson & Johnson: Released one-year data (March 30) for ICOTYDE™, a first-in-class targeted oral peptide.While a pharmaceutical development, it is being paired with new digital adherence monitoring tools specifically designed for European market access. 3. Funding & Innovation Cycles EIC Pathfinder Awards: On April 1, 2026, the European Innovation Council (EIC) awarded €118 million to 30 breakthrough research projects. A significant portion of this funding is directed toward Biotechnology for healthy ageing and Modular Multi-robot platforms for surgical assistance. Horizon Europe (Health): New calls under the HORIZON-HLTH-2026 program are now open for submission.Key areas of interest for MedTech include: Regulatory science to support patient-centred technology. New Approach Methodologies (NAMs) to replace animal testing in medical device validation. Scaling innovation in cardiovascular health, specifically targeting AI-based diagnostic wearables. 4. Sustainability & Circular Economy Circular Economy Act: A coalition of 65 associations, led by MedTech Europe, issued a joint statement this week pushing for harmonized rules in the upcoming Circular Economy Act. The industry is advocating for a "Single Market, Single Rules" approach to allow for the legal refurbishment and recycling of high-value medical components across EU borders. To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email lloyd@nelsonadvisors.co.uk Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Clinical Intelligence: A Strategic Analysis of OpenEvidence and the Multi-Agent Medical AI Ecosystem The evolution of clinical decision support systems (CDSS) has reached a critical inflection point where traditional reference models are being supplanted by agentic, multi-model architectures. At the center of this transition is OpenEvidence, a platform that has ascended to a $12 Billion valuation in less than a year of public operations. This rapid scaling is fundamentally a response to the "human problem" identified by the platform’s founder, Daniel Nadler: the exponential expansion of medical knowledge, which is currently estimated to double every 73 days. For the contemporary physician, staying abreast of even a single sub-specialty would require approximately nine hours of daily reading, an impossibility that creates a systemic "dangerous gap" between breakthrough scientific discoveries and actual patient treatment. OpenEvidence positions itself as the "default operating system of medical knowledge," moving beyond simple search to provide an integrated, ad-supported "brain extender" for verified clinicians. This analysis explores the firm's competitive positioning, technical orchestration, venture capital trajectory and the inherent regulatory risks and growth strategies defining the next generation of medical super-intelligence. The Financial Architecture of Rapid Scaling The funding history of OpenEvidence represents one of the most aggressive capital-raising efforts in the history of healthcare technology. The company’s valuation trajectory, jumping from $1 Billion to $12 Billion within 12 months, reflects an investor consensus that clinical AI is transitioning from an experimental tool to essential infrastructure. The total capital raised by early 2026 reached approximately $750 Million, distributed across four high-velocity rounds. Venture Capital Trajectory and Investor Thesis The investor roster for OpenEvidence includes an elite tier of venture capital and institutional firms, each bringing specific strategic advantages. Lead investors such as Thrive Capital and DST Global are joined by Sequoia Capital, Google Ventures (GV), Nvidia, and the Mayo Clinic. The presence of Nvidia highlights the compute-intensive nature of the firm’s multi-agent architecture, while the Mayo Clinic’s involvement via its Platform Accelerate program provided early clinical validation and institutional trust. Funding Round Date Amount Raised Lead Investor(s) Valuation (Post-Money) Series A February 2025 $75 Million Sequoia Capital $1 Billion Series B July 2025 $210 Million GV, Kleiner Perkins $3.5 Billion Series C October 2025 $200 Million GV $6 Billion Series D January 2026 $250 Million Thrive Capital, DST Global $12 Billion The core thesis driving these investments is the belief that OpenEvidence is successfully bypassing traditional, slow-moving hospital procurement cycles. By utilising a Direct-to-Clinician (DTC) model, where the tool is free for verified doctors, the platform has achieved a daily active use rate of over 40% among U.S. physicians. This bottom-up adoption creates a massive user base that can then be monetised through high margin pharmaceutical advertising and future enterprise-level integrations. Revenue Mechanisms and Market Efficiency OpenEvidence reached a $100 Million annual revenue run rate in less than a year of commercial operations, making it one of the fastest-growing AI companies in any vertical. The monetisation strategy centres on a specialised pharmaceutical advertising model. While consumer social platforms might command Cost Per Mille (CPM) rates between $5 and $15, OpenEvidence’s uniquely targeted audience of verified prescribers commands CPMs between $70 and $1,000+. This allows for an average revenue per user (ARPU) of approximately $124, positioning the company to capture a significant portion of the $20 billion to $25 Billion annual U.S. digital pharma ad spend. Competitive Taxonomy and Market Displacement The clinical AI market is divided into three primary segments: legacy reference platforms, AI-native disruptors, and generalist AI giants. OpenEvidence’s dominance is currently predicated on its ability to bridge the gap between trustworthy, peer-reviewed content and the conversational interface of modern generative models. Legacy Reference Systems vs. AI-Native Models Incumbents such as UpToDate (Wolters Kluwer), DynaMed (EBSCO), and ClinicalKey (Elsevier) have long dominated the point-of-care market through human-authored summaries. However, the time required to navigate these narrative-heavy resources is a significant bottleneck. Comparative studies indicate that OpenEvidence provides a 18% reduction in the time spent answering clinical questions, saving approximately 30 seconds per encounter. Competitor Segment Core Value Proposition Vulnerability UpToDate Legacy Reference 7,400+ physician authors; deep narrative authority High subscription costs; slow to navigate Glass Health AI-Native Diagnostic reasoning; structured differential diagnoses Niche focus on reasoning vs. broad search AMBOSS Med-Ed/Reference Structured knowledge for students and residents Reference-first; less agentic than OpenEvidence OpenAI/Anthropic Generalist AI Massive reasoning power; HIPAA-compliant workspaces Lack of exclusive medical journal partnerships DynaMed Legacy Reference Explicit evidence grading; rapid updates Smaller topic coverage than UpToDate A critical differentiator for OpenEvidence is its "copyright-friendly" strategy. By securing official AI partnerships with the New England Journal of Medicine, JAMA, the NCCN, and the American College of Cardiology, OpenEvidence has created a data moat that protects it from the legal and accuracy-related challenges faced by generalist models like GPT-5 or Claude Healthcare. These partnerships allow the AI to ground its responses in figures, tables, and full-text clinical findings that are often behind paywalls or restricted for general training. The Big Tech Threat and the Focus Moat The entry of OpenAI (ChatGPT Health) and Anthropic (Claude for Healthcare) into the clinical space represents a significant challenge. These firms possess greater compute resources and broader AI research capabilities. However, OpenEvidence’s management argues that healthcare cannot be a "side hustle". The company’s focus on a single vertical, clinicians, allows for a deeper feedback loop, having already processed hundreds of millions of clinical consultations from verified U.S. physicians. This proprietary interaction data serves as a secondary moat, helping to fine-tune the "conductor" model for specific clinical nuances that generalist models may overlook. Technical Orchestration: The Conductor and the Orchestra of Agents OpenEvidence differentiates itself technically by utilising a "multi-AI agentic architecture". Rather than relying on a single, monolithic large language model (LLM) which might struggle with the specialised knowledge required for 160+ medical sub-specialties, the platform uses a hub-and-spoke topology designed to mimic a multidisciplinary care team in a top-tier academic hospital. The Hub-Spoke Topology and Routing Mechanism At the center of this architecture is a "conductor" AI. When a clinician submits a natural language query, the conductor model does not attempt to answer the question immediately. Instead, it performs a high-level intent analysis to determine which clinical expertise is required. The query is then dynamically routed to one or more proprietary, medically specialised sub-specialist models. This architectural choice is driven by the need for accuracy and the mitigation of hallucinations. Hierarchical multi-agent systems are particularly effective for multi-domain platforms where a root orchestrator can manage specialised workers for oncology, cardiology, or neurology. This structure prevents the "quadratic coordination constraint," where the complexity of an agent network scales leading to increased latency and error propagation. By using a directed tree structure, OpenEvidence ensures that communication flows strictly from parent to child, maintaining state isolation and preventing "groupthink" among the models. Synthesis and Verification Once the specialist models provide their outputs, the conductor AI synthesises the information into a single response. A hallmark of this output is the citation labeling system, which identifies sources by relevancy based on a proprietary evidence retrieval algorithm. This allows physicians to verify recommendations in real-time, accessing the underlying peer-reviewed literature directly from the chat interface. The technical excellence of this system is supported by what the firm calls "medical super-intelligence," a multimodal and multi cloud approach that ensures high availability and accuracy for high-stakes decisions at the point of care. Product Ecosystem and Expansion Strategies OpenEvidence has evolved from a medical search engine into a broader clinical workflow platform, categorised by its 2.0 release and the introduction of specialised communication tools. OpenEvidence 2.0 and Administrative Automation The 2.0 platform, launched in late 2024, addresses the "administrative burden" that consumes approximately 7.9 hours of a physician’s weekly schedule. Prior Authorisation: The platform can auto-draft prior authorisation letters, incorporating specific citations and medical evidence to justify treatment plans to insurers. Patient Communication: It generates evidence-based patient handouts and home care instructions, translating complex clinical guidelines into accessible language. Clinical Calculators: Inclusion of over 50 widely used clinical calculators within the primary interface reduces the need for external applications. The Clinical Documentation and Communication Suite The introduction of "Visits" and the "Doctor Dialer" positions OpenEvidence in direct competition with ambient scribe and telemedicine firms. Visits: An ambient clinical assistant that transcribes real-time patient encounters into structured documentation, integrating evidence-based suggestions directly into the draft. Doctor Dialer: A HIPAA-secure, privacy-centric communication tool that allows doctors to call or message patients from their personal devices while displaying their hospital or practice caller ID. This tool has already supported over 37 Million minutes of doctor-patient communication in its limited release phase. Feature Functionality Strategic Intent Medical Search Peer-reviewed synthesis with citations Establish trust and daily habit Visits Ambient scribing and note generation Capture encounter data and reduce burnout Dialer Secure calling and messaging Own the communication layer of the clinical workflow Open Vista Pharma R&D and trial matching Bridge the gap between life sciences and care Strategic Partnerships and Institutional Integration OpenEvidence’s growth is increasingly tied to its ability to embed itself within large-scale health systems and electronic health record (EHR) environments. Enterprise-Scale Deployments: Mount Sinai and Sutter Health In early 2026, OpenEvidence announced several landmark enterprise deals that signal a shift from a clinician-only tool to a system-wide standard of care. Mount Sinai Health System: This collaboration represents the first enterprise-scale deployment to extend access across the full clinical care team, including registered nurses and pharmacists. By embedding OpenEvidence directly into the Epic EHR, Mount Sinai aims to "democratise access" to clinical evidence, ensuring that any staff member can receive grounded answers within their existing workflow. Sutter Health: A similar integration allows Sutter clinicians to perform natural-language evidence searches directly within the Epic environment, solving the "last mile" problem of clinical AI where physicians are often reluctant to open separate browser tabs during a consultation. Life Sciences Collaboration: The Open Vista Initiative The partnership with Veeva to launch "Open Vista" in 2026 aims to leverage OpenEvidence’s reach, currently over 40% of US physicians, to accelerate clinical trial matching and improve the adoption of newly approved medicines. This initiative represents a third-order growth strategy: transitioning from a search tool to a two-sided marketplace connecting the point of care with the pharmaceutical R&D pipeline . Internationalisation and Global Medical Equity While primarily focused on the U.S. market, OpenEvidence has signalled significant plans for global expansion, beginning with English-first markets like the UK, Canada, and Australia. The Rwanda Pilot and Low-Resource Settings A strategic partnership with the Rwanda Biomedical Center (RBC) and "Resolve to Save Lives" (RTSL) highlights the platform’s potential for global health. In Rwanda, where access to current medical literature and specialist consultation is often limited, 45 leading clinicians are testing a customised version of OpenEvidence adapted for local resource constraints and specific knowledge requirements. This pilot serves as a blueprint for adapting clinical AI for low- and middle-income countries, aiming to reduce global inequities in the quality of care. Content Localisation and Multilingual Capabilities To support its global ambitions, OpenEvidence is developing multilingual capabilities. The partnership with Wiley, which includes over 400 journals and authoritative textbooks like Yamada's Textbook of Gastroenterology and Rook's Dermatology Handbook , provides the deep content library necessary for international specialists. This expansion of the "evidence layer" ensures that the platform remains grounded in peer-reviewed literature even as it adapts to different regional guidelines and medical practices. Risks, Regulatory Challenges and Performance Realities Despite its meteoric rise, OpenEvidence faces non-trivial risks regarding accuracy, regulatory classification, and the sustainability of its monetisation model. The Accuracy and Benchmark Controversy OpenEvidence has claimed to "ace" the USMLE with a perfect score, but independent quantitative evaluations have presented a more nuanced picture. In a study using the MedXpertQA dataset, which consists of complex medical subspecialty scenarios, OpenEvidence achieved an accuracy of only 34% to 41%. Furthermore, a large-scale assessment using a 1,000-item benchmark (combining MedQA and HealthBench tasks) found that generalist models like GPT-5 and Gemini 3 Pro outperformed specialised clinical tools in terms of completeness, communication quality, and systems-based safety reasoning. Model MedQA Accuracy HealthBench Consensus Score GPT-5 96.2% 97.0% Gemini 3 Pro 94.6% 90.5% OpenEvidence 89.6% 74.3% UpToDate Expert AI 88.4% 75.2% These findings suggest that while RAG-based systems are excellent for providing citations, the "reasoning" layer of generalist models may still be superior for complex clinical synthesis. There is a risk that if physicians become over-reliant on AI and the "conductor" model fails to route a question correctly, dangerous clinical errors could occur. Regulatory Classification: FDA SaMD The regulatory status of OpenEvidence as a "Software as a Medical Device" (SaMD) is a subject of ongoing debate. The FDA classifies medical software based on its intended use and the significance of the information it provides for decision-making. FDA Class Risk Description Regulatory Pathway Class I Low risk (General wellness, administrative tasks) Usually exempt Class II Moderate risk (Diagnosis, monitoring of non-life-threatening conditions) 510(k) or De Novo Class III High risk (Life-sustaining or high-risk diagnosis) Premarket Approval (PMA) OpenEvidence currently positions itself as a clinical decision support tool that "supports a healthcare professional but does not offer diagnosis or treatment" and "enables providers to independently review recommendations". This positioning typically allows for classification as a lower-risk device or even an exemption from certain premarket notifications. However, as the platform moves toward "medical super intelligence" and automates more of the diagnostic and treatment-planning workflow, the FDA may require more rigorous 510(k) clearances, particularly if the AI is seen as "driving" rather than just "informing" clinical management. Institutional Trust and Ethical Considerations The reliance on pharmaceutical advertising for monetisation introduces potential conflicts of interest. Critics may argue that an ad-supported model could subtly bias AI-generated treatment recommendations toward products from sponsors. OpenEvidence mitigates this by emphasising that its models are trained only on peer-reviewed journals and that advertising is displayed in the interface rather than integrated into the generated answers. Nevertheless, maintaining "brand trust" among a skeptical physician community remains a critical strategic priority. Clinical Intelligence: A Strategic Analysis of OpenEvidence and the Multi-Agent Medical AI Ecosystem M&A Potential: Targets and Exit Scenarios With a $12 Billion valuation and $750 Million in capital, OpenEvidence is positioned as a major consolidator in the healthcare AI space. Strategic Acquisition Targets The company has already demonstrated interest in acquisitions, reportedly acquiring the firm Amaro. Potential future targets include: Specialised AI Startups: Firms like Nested Knowledge (evidence-based medical search) or iDoctus and Ciplamed (regional medical platforms) could accelerate international expansion and content depth. Ambient Scribing Leaders: To bolster its "Visits" feature, OpenEvidence might target companies like Abridge Inc.or Nabla, which have deep experience in ambient documentation and EHR integration. Workflow Optimisation Tools: Startups focusing on prior authorisation automation or ICD-10 coding could further reduce the administrative burden for OpenEvidence users. Potential Acquirers While Daniel Nadler has expressed a commitment to independence, the scale and valuation of OpenEvidence make it a prime target for several types of acquirers : EHR Giants: Epic Systems or Oracle/Cerner could seek to acquire the platform to integrate the "default medical OS" into their proprietary ecosystems, offering a massive advantage to their hospital clients. Big Tech Players: Google (Alphabet), a major investor through GV, could seek to fully integrate OpenEvidence into its healthcare AI stack. Legacy Information Providers: Wolters Kluwer (UpToDate) or Elsevier could seek a defensive acquisition to pivot their business models toward generative AI. Conclusion: The Path Toward Medical Superintelligence OpenEvidence has successfully transitioned from a specialized research tool to a high-valuation infrastructure play by identifying and addressing the fundamental information bottleneck in modern medicine. Its success is rooted in a unique combination of high-fidelity data partnerships, a capital-efficient DTC adoption model and a sophisticated multi-agent technical architecture. However, the next phase of its evolution will be defined by its ability to maintain clinical accuracy in sub-specialty domains and navigate an increasingly complex regulatory landscape. The integration into major health systems like Mount Sinai and the expansion into administrative automation suggest that OpenEvidence is well on its way to becoming an essential layer of the clinical workflow. As the "human problem" of information overload persists, the adoption of "brain extenders" is no longer optional but a prerequisite for the safe and effective practice of medicine in the 21st century. The ultimate measure of OpenEvidence’s success will be its ability to translate its $12 Billion valuation into improved patient outcomes and a measurable reduction in the global gap between medical science and medical practice. Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Key Dynamics of the K-Shaped HealthTech Market The global healthtech ecosystem has entered a period of profound structural bifurcation, evolving away from the uniform cyclicality that defined previous decades toward a "K-shaped" trajectory. This dynamic represents a market reality where a distinct upper arm, composed of high-growth, clinically validated and AI-native "Health Tech 2.0" companies, achieves record valuations and operational scale, while a lower arm of legacy point solutions, high-burn startups, and undifferentiated wellness applications faces stagnation or liquidation. This divergence is not merely a financial artefact of high interest rates but a fundamental shift in the operating logic of the healthcare industry, where the premium has moved from "growth at all costs" to "profitable efficiency" and "measurable clinical ROI". The Theoretical Framework of K-Shaped Healthtech Recovery The transition to a K-shaped market marks a departure from traditional economic recovery models. While V-shaped recoveries imply a rapid industry-wide rebound and U-shaped recoveries suggest a prolonged but eventual uniform uplift, the K-shape describes a two-tier outcome where different segments of the same sector experience diametrically opposed fates. In the healthtech context, this began as a post-pandemic correction in 2022 and 2023, but by 2025, it hardened into a permanent structural feature. The upward arm reflects a "winner-take-most" dynamic, where capital concentration, technological superiority (specifically in Generative AI), and deep integration into clinical workflows create insurmountable moats. Conversely, the downward arm is populated by companies suffering from "valuation baggage", startups that raised capital at 20x to 50x revenue multiples during the 2021 peak but failed to achieve sustainable unit economics or product-market fit in a high-rate environment. The current environment amplifies long-standing inequality within the business landscape. Business revenue for firms focused on lower-income segments or those lacking clear efficiency gains is more vulnerable than for firms focused on wealthier clientele or systemic infrastructure. This dispersion risk means that headline indicators, such as total venture funding, can be deceptive. While aggregate funding for U.S. digital health startups rose to $14.2 Billion in 2025, a significant 35% increase from 2024, the total deal count actually dropped by 5%. This indicates that capital is no longer being distributed broadly across the "innovation engine" but is instead being funneled into a select few "Goliaths" that investors view as de-risked bets. Market Indicator 2024 Benchmark 2025 Observed 2026 Forecast Total U.S. Funding $10.5B $14.2B $17.0B - $18.0B Deal Volume (Count) 509 482 450 - 475 Average Deal Size $20.7M $29.3M $32.0M+ Mega-Deal Share (> $100M) 21% 42% 45% - 50% Series B Average Size $29.3M $51.6M $55.0M AI-Enabled Funding Share 37% 54% 60%+ Capital Dynamics and the Rise of the Mega-Fund The financial engine of the K-shaped market is the emergence of the "mega-fund", venture capital firms with at least $500 million to deploy, such as Andreessen Horowitz (a16z), General Catalyst, and Kleiner Perkins. These firms have become the primary market-makers, responsible for the vast majority of mega-deals (raises over $100 Million). In 2025, 80% of all mega-deals featured a mega-fund on the term sheet. This creates a self-reinforcing loop: these "winner" companies receive the capital necessary to out-invest competitors in R&D and customer acquisition, while the "have-nots" are forced into austerity measures, leading to a "thinning of the middle". This concentration is particularly evident in the Series B and C stages, which have become the "valley of death" for many healthtech startups. While Series A activity remains robust as investors seek "fresh" companies without the valuation overhang of 2021, the bar for Series B has risen dramatically. Companies in the middle must now demonstrate not just growth, but a "Rule of 40" performance (growth rate plus free cash flow margin) to attract follow-on capital. For instance, Hinge Health, a representative of the Health Tech 2.0 cohort, reported 72% annualised revenue growth with 26% free cash flow margins in late 2025, a performance that investors now view as the gold standard. Startups unable to reach these benchmarks are finding themselves reliant on unlabeled bridge or extension rounds, which accounted for 35% of all financings in 2025. The M&A landscape further illustrates this K-shaped divergence. Activity surged 61% to 195 deals in 2025, but the nature of these transactions was split. On the upward arm, strategic acquisitions were used to build "horizontal platforms." Examples include Innovaccer acquiring Humbi AI to expand its hospital infrastructure and CoachCare acquiring VitalTech to deepen its care coordination capabilities. These are offensive moves designed to prevent incumbents like Epic or Oracle from replicating feature sets. On the downward arm, however, M&A increasingly took the form of "distress sales" by companies that could not clear the necessary hurdles for subsequent funding. Private Equity (PE) has been a significant beneficiary of this, with a 600% increase in healthtech spend in 2025 as firms snap up distressed assets with solid underlying IP but broken capital structures. The "Health AI X Factor": Causal Mechanisms of Growth Artificial Intelligence is the primary technological driver of the K-shaped bifurcation. It is no longer viewed as a novelty but as "bedrock infrastructure" for the next generation of healthcare companies. In 2025, AI-enabled companies commanded a 19% premium on average deal size, reflecting an investor belief that AI can fundamentally alter the unit economics of healthcare delivery. Bessemer Venture Partners identifies this as the "Health AI X Factor," which provides four distinct competitive advantages: unprecedented velocity, margin expansion, platform potential, and clinical outcomes. Scaling velocity has historically been the primary weakness of healthcare software. Due to long sales cycles, complex integrations, and the "human-intensive" nature of care, it often took a decade or more for companies to reach $100 million in ARR. AI-native companies, however, are hitting these milestones in under five years. This is achieved by automating the "operating layer" of healthcare, specifically clinical and non-clinical workflows, which captured 42% of total sector funding in 2025. Companies like Abridge and OpenEvidence have transitioned from promising pilots to essential infrastructure by automating documentation and triage, reducing clinician burnout, and cutting documentation time by 30 minutes per day per provider. Health AI Pillar Mechanism of Action Strategic Implication Unprecedented Velocity AI accelerates R&D and sales cycles Compression of time-to-scale ($100M ARR in <5 yrs) Margin Expansion Automation of administrative labor Non-linear scaling; revenue growth outpaces headcount Platform Potential Move from point solution to OS Integration into EHR/EPR as essential infrastructure Clinical Outcomes Precision diagnostics and triage Shift to "clinician-in-the-loop" decision support The competitive landscape for AI is now a battle between "agentic" systems developed by tech giants and specialized clinical tools from independent innovators. Amazon Connect Health, launched in late 2025, represents a major move into this space, offering a system that handles everything from patient verification and scheduling to ambient documentation and medical coding. By integrating natively with Epic, the largest U.S. EHR system, Amazon is positioning itself as a core utility for providers. This challenges independent "scribe" startups to either build broader horizontal platforms or risk being commoditised by the cloud giants who own the underlying data infrastructure. Market Generations: Health Tech 1.0 vs. 2.0 The K-shaped market is best understood as a generational split. "Health Tech 1.0" (roughly 2015-2021) was defined by top-line growth fueled by pandemic tailwinds, often at the expense of unit economics and business model sustainability.This cohort remains essentially flat in public markets, with many companies trading below their IPO prices or struggling with high churn. "Health Tech 2.0" (2024-2026), by contrast, is a new class of companies—including Waystar, Tempus, HeartFlow,and Omada Health, that represent a more disciplined approach to healthcare innovation. These 2.0 companies are characterized by profitable or near-profitable operations and proven ROI that works regardless of macroeconomic conditions. In 2025, new health tech stocks rose by 18%, matching the performance of the S&P 500 and significantly eclipsing the Nasdaq Emerging Cloud Index, which fell 7%. This "comeback story" in the public markets has reopened the IPO window, with six companies going public between 2024 and 2025, adding $36.6 billion in fresh market capitalization. However, a "trust gap" remains: even these 2.0 companies trade at a 10-20% discount compared to high-growth software in other sectors, as investors wait for multiple quarters of proven sustainability before awarding them SaaS-level multiples. Feature Health Tech 1.0 (Legacy) Health Tech 2.0 (Modern) Primary Value Prop "Digital Front Door" / Access Clinical ROI / Workflow Efficiency Economic Logic Growth at all costs (VC-subsidized) Profitable efficiency / High FCF Business Model Often B2C or shallow B2B Deeply embedded B2B / Infrastructure Public Market View Discounted; high volatility Rebounding; "Gold Standard" emerging AI Integration Bolt-on or superficial Native; "Agentic" workflows The Consumer Paradox: More Striving, Less Thriving The K-shaped dynamic extends beyond balance sheets into the lives of consumers and patients. A global study of 300,000 voices reveals a profound "progress-sentiment gap": while quality-of-life indicators are at all-time highs, people report feeling 9% worse physically and mentally than in previous years. This is the "wellness treadmill", a pattern of higher effort yielding diminishing emotional returns, where "better" is never quite good enough. This mental health decline, down 11% since 2022—has made behavioural health the strongest driver of telehealth adoption, accounting for 63.9% of all telehealth claims in late 2025. However, the way consumers interact with health technology is bifurcating by income. Households earning over $150,000 are increasing their spend on "thriver" categories like longevity, preventative care, and out-of-home experiences, with spending growth approaching 20%. Conversely, lower-income households (<$50,000) are trading down, delaying purchases, or relying on credit to cover basic health needs. This split has revitalised the D2C market for specialised clinical services. While generic wellness apps are struggling, 2025 saw a wave of activity in D2C lab testing from companies like Oura, Whoop, and Hims. This trend is driven by younger consumers (Gen Z and Millennials) who are twice as likely as older generations to use natural products and cutting-edge digital technologies, provided they see data-backed evidence of efficacy. The "wellness" market, now valued at $2 trillion globally, is becoming increasingly segmented: one side seeks price efficiency for basic needs, while the other seeks time efficiency and scientific expertise at any price. Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Regulatory Catalysts: The Access and Outcome Mandate Regulatory bodies in 2025 and 2026 are acting as decisive market-makers, further entrenching the K-shaped divide. The Centers for Medicare & Medicaid Services (CMS) and the FDA have shifted their focus toward "accountability and integration" rather than mere "innovation promise". The CMS "ACCESS Model" (Advanced Care Coordination through Enhanced Support Services), launching in 2026, exemplifies this shift. It moves away from fee-for-service toward "outcome-aligned payments," where providers are rewarded based on the share of patients meeting outcome targets for chronic conditions like hypertension, diabetes and musculoskeletal pain. To support this, the "TEMPO" pilot allows manufacturers of devices that have not yet received full FDA authorisation to be used within the ACCESS model, generating real-world data to support future marketing submissions. This creates a massive competitive advantage for companies with integrated, technology-supported care models over those selling isolated point solutions. Simultaneously, the FDA has tightened its oversight of "wellness" claims. A 2025 warning letter to WHOOP regarding its blood pressure insights signaled that any technology intended for diagnosis or mitigation of disease would be strictly regulated as a medical device. This "regulatory floor" is rising; the requirement for "total product lifecycle" (TPLC) monitoring and rigorous data stewardship means that smaller startups without the capital for clinical trials or regulatory consultants are increasingly locked out of the market. Regulatory Initiative Focus Area Market Winner ACCESS Model (CMS) Outcome-aligned payments Integrated care platforms (RPM/CCM) TEMPO Pilot (FDA) Real-world data generation Fast-track device manufacturers Part D Redesign (IRA) Manufacturer cost-sharing Efficient "TechBio" platforms PCCP Framework Adaptive AI evolution "Safe and Transparent" AI models Procurement Act 2023 (UK) Value over price Clinically validated SME partners In the United Kingdom, the NHS has embarked on a similar "left shift," moving care from acute hospitals to community settings. The shift to Value-Based Procurement (VBP) in 2026 marks the end of "cheapest price wins". Procurement decisions must now evidence long-term patient outcomes and total pathway cost savings. While this favours high-quality innovators, it places a massive administrative burden on SMEs, who account for 85% of the 80,000 NHS suppliers but struggle to navigate the "patchwork of frameworks" across 42 Integrated Care Systems. Cybersecurity as a Strategic Gatekeeper Cybersecurity has transitioned from a backend technical requirement to a primary differentiator for market access. In 2024 and 2025, the healthcare sector faced its most severe wave of cyberattacks, with 92% of organizations reporting a breach. The average cost of a healthcare breach has risen to $408 per record—three times higher than the cross-industry average. In this climate, "security rigor" is a prerequisite for even entering an RFP. The K-shaped divide is visible in certification adoption. HITRUST has emerged as the "gold standard" for regulated healthcare environments, offering a prescriptive framework that simplifies vendor evaluation and builds "instant credibility" with buyers and investors. While SOC 2 is often seen as a "legal floor" or "baseline," hospital systems and large payers are increasingly mandating HITRUST for any vendor touching ePHI. Achieving this certification can provide a 464% ROI by speeding up sales cycles by up to 50%. Companies on the lower arm of the K that neglect this "security-by-design" find themselves increasingly excluded from the $125 billion that the healthcare industry is projected to spend on cybersecurity products through 2025. The Extinction Event: Anatomy of Failure in the Lower Arm The downward arm of the K-shaped market is defined by a series of high-profile failures and liquidations. The "cleansing" of the market has targeted companies that relied on "fake it till you make it" strategies or those that failed to diversify after pandemic demand peaked. Builder.ai , which raised $445 Million at a $1.3 Billion valuation, filed for bankruptcy in May 2025 after revelations that its "AI-powered" development was largely performed by offshore human labour, a case of "wearing a fake moustache and calling it innovation". Similarly, companies like Cue Health and Wheel Health, which built their business models on COVID-19 testing and travel nurse demand, respectively, collapsed as demand normalized and they lacked a sustainable pivot. These failures underscore a broader lesson: in a K-shaped economy, market timing is everything, but surviving the "inevitable correction" requires actual technology and financial governance (such as hiring a CFO, which Builder.ai notably lacked for two years). Company Status Primary Cause of Decline/Failure Builder.ai Bankruptcy (2025) Fraudulent AI claims; high burn without CFO Cue Health Collapsed (2023-24) Post-pandemic demand collapse (testing) Babylon Health Insolvency (2023) Low-margin, unsustainable telehealth model Olive AI Liquidated (2023) High integration complexity; over-expansion Lilium Insolvency (2025) High regulatory barriers; technical failure Cerebral Restructured (2024) DOJ/DEA investigation into prescribing The collapse of these "Health Tech 1.0" stars has cleared the way for the "Health AI X Factor" cohort to capture market share. However, it has also raised the risk premium for the entire sector. Even high-quality assets are being priced lower due to "elevated risk premiums" and "geopolitical exposure" (particularly related to China licensing and API sourcing).Due diligence now routinely includes modelling for trade policy shocks and the impact of the Inflation Reduction Act on pricing corridors. Case Study: The "Goliath" vs. "David" Workflow War The concentration of power among "Goliaths" is the most significant competitive dynamic of 2026. This is best observed in the struggle for control over the "healthcare workflow stack." In 2025, clinical and non-clinical workflow captured $5.96 billion in funding, a massive lead over any other category.Abridge and OpenEvidence emerged as the "infrastructure" winners, using mega-deals to move from point solutions to horizontal platforms. At the same time, Amazon's entry with "agentic AI" through Amazon Connect Health has created a new baseline for what "good" looks like: a system that is available 24/7, integrates with Epic, and handles the full patient journey from initial call to final billing. Independent "Davids" are responding by buying each other to build horizontal breadth before the giants can move. For example, Judi Health raised $400 million and immediately acquired Amino Health to expand into patient navigation. This "strategic acceleration" is a defensive necessity; without scale, point solutions face the risk of being reduced to "features" within the EHR or cloud providers' ecosystems. Conclusion: Strategic Imperatives for the 2026-2027 Cycle The K-shaped healthtech market is no longer a temporary phenomenon but a structural reality defined by the "haves" of AI infrastructure and the "have-nots" of legacy models. For stakeholders to navigate this divide, several strategic imperatives have emerged: Prioritise Profitable Efficiency over Raw Growth: The "Health Tech 2.0" gold standard is the Rule of 40. Companies must demonstrate a clear path to $100 Million ARR within five years while maintaining strong free cash flow margins. Embed AI into the Core Operating Layer: Success is no longer about "using AI" but about owning the workflow. The market rewards systems that provide "agentic" solutions, handling complex, multi-step tasks that reduce human labour costs. Secure "Gold Standard" Certifications: Trust is a market gatekeeper. HITRUST certification has moved from optional to mandatory for high-value contracts, providing a tangible ROI by accelerating sales and reducing audit friction. Align with Value-Based and Outcome-Driven Policy: Both the CMS (ACCESS/TEMPO) and the NHS (VBP) are rewarding integrated, data-rich models that prove long-term cost savings. Pure-play software without clinical evidence will struggle to maintain reimbursement. Target the "Thriver" Demographic or Engineer Strategic Affordability: The consumer split requires a two-track product strategy. Premium, high-expertise products will find growth at the top of the income arm, while value-driven, "essential" services must focus on radical price efficiency to serve the squeezed middle and lower cohorts. As the market heads toward 2027, the "IPO window" will likely remain open only for those on the upward arm of the K. The "tale of two markets" will continue to unfold, with the few that demonstrate durability and scale capturing the vast majority of the $6 trillion in projected worldwide IT spending. The healthtech industry is no longer about the "promise of innovation" but about the "rigor of impact". Nelson Advisors > European MedTech and HealthTech Investment Banking   Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @  https://www.healthcare.digital     Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today!  https://lnkd.in/e5hTp_xb    Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors   #HealthTech   #DigitalHealth   #HealthIT   #Cybersecurity   #HealthcareAI   #ConsumerHealthTech   #Mergers   #Acquisitions   #Partnerships   #Growth   #Strategy   #NHS   #UK   #Europe   #USA   #VentureCapital   #PrivateEquity   #Founders   #SeriesA   #SeriesB   #Founders   #SellSide   #TechAssets   #Fundraising   #BuildBuyPartner   #GoToMarket   #PharmaTech   #BioTech   #Genomics   #MedTech Nelson Advisors LLP   Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events   Digital Health Rewired > March 2026 > Birmingham, UK    NHS ConfedExpo   >  June 2026 > Manchester, UK    HLTH Europe >  June 2026, Amsterdam, Netherlands   HIMSS AI in Healthcare  >  July 2026, New York, USA   Bits & Pretzels >  September 2026, Munich, Germany     World Health Summit 2026  >  October 2026, Berlin, Germany   HealthInvestor Healthcare Summit >  October 2026, London, UK  HLTH USA 2026 >  October 2026, USA   Barclays Health Elevate >  October 2026, London, UK    Web Summit 2026 >  November 2026, Lisbon, Portugal     MEDICA 2026 >  November 2026, Düsseldorf, Germany   Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk